



(86) Date de dépôt PCT/PCT Filing Date: 2014/01/14
(87) Date publication PCT/PCT Publication Date: 2014/07/17
(85) Entrée phase nationale/National Entry: 2015/07/10
(86) N° demande PCT/PCT Application No.: US 2014/011418
(87) N° publication PCT/PCT Publication No.: 2014/110552
(30) Priorités/Priorities: 2013/01/14 (US61/752,232);
2013/08/27 (US61/870,570)

(51) Cl.Int./Int.Cl. *A01K 67/027* (2006.01),
C12N 15/63 (2006.01), *C12N 15/85* (2006.01),
C12N 5/07 (2010.01)
(71) Demandeur/Applicant:
RECOMBINETICS, INC., US
(72) Inventeurs/Inventors:
FAHRENKRUG, SCOTT C., US;
CARLSON, DANIEL F., US
(74) Agent: MACPHERSON LESLIE & TYERMAN LLP

(54) Titre : BETAIL SANS CORNE
(54) Title: HORNLESS LIVESTOCK




FIG. 2

(57) **Abrégé/Abstract:**

Compositions and methods for making livestock with a polled allele are presented, including migrating a polled allele into a bovine species without changing other genes or chromosomal portions. Animals may be genetically modified so that they do not have horns. One such process involves introgression of the bovine polled allele. A livestock breed is thus made to receive the polled allele without change to their other traits. An embodiment of the invention is a genetically modified livestock animal comprising a genomic modification from a horned allele to a polled allele.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(10) International Publication Number
WO 2014/110552 A1(43) International Publication Date
17 July 2014 (17.07.2014)

(51) International Patent Classification:

A01K 67/027 (2006.01) *C12N 15/63* (2006.01)
C12N 5/07 (2010.01) *C12N 15/85* (2006.01)

(21) International Application Number:

PCT/US2014/011418

(22) International Filing Date:

14 January 2014 (14.01.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/752,232 14 January 2013 (14.01.2013) US
 61/870,570 27 August 2013 (27.08.2013) US

(71) Applicant: **RECOMBINETICS, INC.** [US/US]; 1246 University Avenue West, Suite 301, Saint Paul, MN 55104 (US).

(72) Inventors: **FAHRENKRUG, Scott, C.**; 2751 Hayes Street NE, Minneapolis, MN 55418 (US). **CARLSON, Daniel, F.**; 6816 Benton Circle, Inver Grove Heights, MN 55076 (US).


(74) Agents: **HERBERT, Curtis, B.** et al.; Dardi & Herbert, PLLC, Moore Lake Plaza, Suite 205, 1250 East Moore Lake Drive, Fridley, MN 55432 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

[Continued on next page]

(54) Title: HORNLESS LIVESTOCK



(57) Abstract: Compositions and methods for making livestock with a polled allele are presented, including migrating a polled allele into a bovine species without changing other genes or chromosomal portions. Animals may be genetically modified so that they do not have horns. One such process involves introgression of the bovine polled allele. A livestock breed is thus made to receive the polled allele without change to their other traits. An embodiment of the invention is a genetically modified livestock animal comprising a genomic modification from a horned allele to a polled allele.

FIG. 2

WO 2014/110552 A1



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, — *with sequence listing part of description (Rule 5.2(a))*
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

HORNLESS LIVESTOCK

CROSS REFERENCE TO RELATED APPLICATIONS

The application claims priority to U.S. Provisional Application Nos. 61/752,232 filed
5 January 14, 2013 and 61/870,570 filed August 27, 2013, each of which are hereby incorporated
by reference herein.

STATEMENT OF GOVERNMENT SUPPORT

Aspects of the work described herein were supported by grant 1R43RR033149-01A1
10 from the National Institutes of Health and Biotechnology Risk Assessment Program
competitive grant number 2012-33522-19766 from the USDA - National Institute of Food and
Agriculture. The United States Government may have certain rights in these inventions.

TECHNICAL FIELD

15 The technical field relates to genetically modified organisms such as cells, or animals
that do not have horns.

BACKGROUND

Livestock horns are, in various species, removed to make raising the animals easier.
20 There are a number of approaches to removing these horns.

SUMMARY

Animals may be genetically modified so that they do not have horns. One such process
involves introgression of the bovine *polled* allele. A livestock breed is thus made to receive the
25 polled allele without change to their other traits.

An embodiment of the invention is a genetically modified livestock animal comprising
a genomic modification from a horned allele to a polled allele. The may be a first breed of
animal that has the horned allele and the polled allele is found in a second breed of animal.
The polled allele may be natural or synthetic.

30 An embodiment of the invention is an in vitro cell comprising a genomic modification to
a horned allele of the cell. The modification at the horned allele (horned locus) is a modification
from the horned allele to a polled allele. The cell may be a livestock cell.

An embodiment of the invention is a method of creating a genetically modified livestock
organism comprising altering a native horned allele of a livestock primary cell, a livestock primary

somatic cell, a livestock stem cell, a livestock primordial germ cell, a livestock zygote, a livestock blastocyst, or a livestock embryo, with the horned allele being altered to a polled allele.

Embodiments include any of the above methods comprising exposing the cells to the homing endonuclease (site-specific endonuclease) without a reporter gene, creating colonies
5 of clonal cells, and testing a subset of members of the colonies to identify colonies incorporating the modification at the targeted chromosomal site.

Further embodiments are directed to an organism (a genetically modified animal, a genetically modified founder animal, or a genetically modified cell) prepared according to one or more of these methods. Embodiments include plasmids, vectors, and isolated nucleic acids
10 involved in these techniques, e.g., site-specific endonucleases and HDR templates and vectors for expressing the same.

Embodiments of the invention include uses of the modified cells for making livestock animals. Cloning is one technique for making the animals.

Embodiments include uses of the modified animals or their progeny as livestock. The
15 methods for making the cells or animals may be for making a livestock founder animal with a polled phenotype.

The following patent applications are hereby incorporated herein by reference for all purposes; in case of conflict, the specification is controlling: US 2010/0146655, US 2010/0105140, US 2011/0059160, US 2011/0197290, U.S. Serial No. 13/404,662 filed
20 February 24, U.S. Serial No. 61/446,651 filed February 25, 2011, U.S. Serial No. 61/662,767 filed June 21, 2012, and 13/594,694 filed August 24, 2012. Each of these patent applications is hereby incorporated by reference herein for all purposes.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1. Panel a) Schematic of the bovine horned/polled locus. TALENs were designed
25 to cut the horned variant where indicated by arrowheads. Panel b) The sense strand sequence of four TALENs. Panel c) Surveyor assay of horned Holstein fibroblasts cells three days post transfection with mRNA encoding each TALEN pair. TALEN ID and incubation temperature post transfection are indicated above the gel. Sequence identifiers as follows: HP1.1 left and
30 right (SEQ ID NOS: 1 and 2); HP1.2 left and right (SEQ ID NOS: 3 and 4); HP1.3 left and right (SEQ ID NOS: 5 and 6); HP1.4 left and right (SEQ ID NOS: 7 and 8).

Fig. 2. TALEN-mediated introgression of *POLLED*. Panel a) A schematic of the strategy to introgress the *Polled* allele into Holstein (*HORNED*) cells. The *POLLED* allele,
bottom, is a tandem repeat of 212bp (red arrow) with a 10bp deletion (not shown). TALENs

were developed to specifically target the *HORNED* allele (green vertical arrow) which could be repaired by homologous recombination using the *POLLED* HDR plasmid. Panel b) Representative images of colonies with homozygous or heterozygous introgression of *POLLED*. Three primer sets were used for positive classification of candidate colonies:

5 F1+R1, F2+R2 and F1+P (*POLLED* specific). Identity of the PCR products was confirmed by sequencing F1+R1 amplicons.

Fig. 3. Example of polled conversion in an isolated colony. Individual colonies were propagated from cell populations described in Fig 2. Each colony was analyzed by the PCR method described in Fig 2. Clone 3 has a product at both 389 and 591 bp (arrow) indicative of
10 a heterozygous conversion to the polled allele. The Repair Template used was 591 residues in length.

Fig. 4. Panel a) Schematic to convert a horned allele to a polled allele. HP1.3 TALENs plus a short repair template are introduced into horned cells. The repair template was generated by PCR from polled Angus genomic DNA; homology lengths are indicated. Panel b) PCR
15 assessment of polled conversion in horned Holstein fibroblasts transfected with 2 µg of TALEN mRNA + 500 ng of ssDNA coated with Gal4:RecA. Each lane/PCR reaction consists of ~3 cell equivalents diluted from a transfected population. PCR using primers btHP-F1 and btHP-R1 from horned cells results in a product of 389 bp. Conversion to polled results in a net insertion of 202 base pairs; thus the PCR product of the same primers results in a 591 bp product
20 (arrow in left margin). The number of reactions with products indicative of polled conversion is shown in the upper right corner. Panel c) PCR assessment of polled conversion in horned Holstein fibroblasts transfected with 2 ug of TALEN mRNA + 1,500 ng of ssDNA. The number of reactions with products indicative of polled conversion is shown in the upper right corner.

25 Fig. 5 Comparison of TALENs and CRISPR/Cas9 mediated HDR at porcine APC. Panel a) APC14.2 TALENs (SEQ ID NOS: 9 and 10) and the gRNA sequence APC14.2 G1a (SEQ ID NO: 12) are shown relative to the wild type *APC* sequence (SEQ ID NO: 11). Below, the HDR oligo (SEQ ID NO: 13) is shown which delivers a 4bp insertion resulting in a novel HindIII site. Pig fibroblasts transfected with 2µM of oligo HDR template, and either 1µg
30 TALEN mRNA, 1 µg each plasmid DNA encoding hCas9 and the gRNA expression plasmid; or 1 µg mRNA encoding hCas9 and 0.5 µg of gRNA expression plasmid, were then split and cultured at either 30 or 37°C for 3 days before expansion at 37°C until day 10. Panel b) Charts displaying RFLP and Surveyor assay results.

DETAILED DESCRIPTION

As reported herein, hornless livestock animals have been made using genetic techniques. Animals that typically have horns but, because of spontaneous mutations, do not have horns, are called *polled* animals. To protect the welfare of dairy farm operators and cattle, horns are routinely manually removed from the majority of dairy cattle in the U.S., Europe, and in other regions. De-horning is painful, elicits a temporary elevation in animal stress, adds expense to animal production and, despite the intent of protecting animals from subsequent injury, the practice is viewed by some as inhumane. Some beef breeds are naturally horn-free (e.g., Angus), a trait referred to as *POLLED* that is dominant. The techniques set forth herein improve animal well-being by providing animals that do not have to undergo dehorning. Two allelic variants conferring *polledness* have recently been identified on chromosome 1. Dairy cows with either of these mutations are rare and generally rank much lower on the dairy genetic selection indices than their horned counterparts. Meiotic introgression of the *POLLED* allele into horned breeds can be accomplished by traditional crossbreeding, but the genetic merit of crossbred animals would suffer and require many lengthy generations of selective breeding to restore to productivity.

Geneticists have hunted for the genetic locus of polledness for decades. In brief, polledness has been an object of intense modern research for twenty years. *See* Allais-Bonnet et al. (2013) Novel Insights into the Bovine Polled Phenotype and Horn Ontogenesis in *Bovidae*. *PLoS ONE* 8(5):e63512. The polled mutation was quickly mapped to bovine chromosome 1 in many breeds, but the actual site of the genetic cause of polledness was elusive for various reasons. Quite recently, however, it was shown that there are at least two polled alleles (one “Celtic” and one “Friesian”) and candidate mutations were proposed for each of them. Medugorac et al. (2012) Bovine polledness - an autosomal dominant trait with allelic heterogeneity. *PLoS One* 7:e39477. None of these mutations were located in known coding or regulatory regions. Herein, the inventors show that making genetic changes at comparable sites in non-polled (horned) animals can result in polled phenotypes.

It is possible, however, to create *polledness* in animals, and to do so without disturbing the animals’ genome. The non-meiotic introgression of the Celtic *POLLED* allele (also referred to as Pc allele) (duplication of 212 bp that replaces 10bp) was achieved in fibroblasts derived from horned dairy bulls. A plasmid HDR template containing a 1594bp fragment including the Celtic *POLLED* allele was taken from the Angus breed (Fig. 1 panel a). TALENs were designed such that they could cleave the *HORNED* allele but leave the *POLLED* allele unaffected. Surprisingly, this experiment showed that one pair of TALENs delivered as mRNA

had similar activity compared to plasmid expression cassettes (data not shown). Accordingly, experiments were performed that delivered TALENs as mRNA to eliminate the possible genomic integration of TALEN expression plasmids. Five of 226 colonies (2%) passed each PCR test shown in Fig. 1 panel b to confirm introgression of *POLLED*. Three of the five clones
5 were homozygous for *POLLED* introgression and confirmed by sequencing to be 100% identical to the intended allele (data not shown).

Traditional breeding programs based on animal mating or artificial reproductive techniques involve mixing many genes in the hope of ultimately producing a good combination of genes that create or combine desirable traits. Transgenic techniques hold out a promise of
10 accelerating traditional breeding processes. Some drawbacks of transgenic processes are that the processes, while an improvement, are nonetheless slow, costly and labor-intensive. Low efficiencies and unpredictability in results are normal. Further, processes that make a change only at an intended genomic site are not conventionally known.

The inventors have developed precise, high frequency editing of a variety of genes in
15 about various livestock cells and/or animals that are useful for agriculture, for research tools, or for biomedical purposes. These livestock gene-editing processes include TALEN and CRISPR/Cas9 stimulated homology-directed repair (HDR) using plasmid, rAAV and oligonucleotide templates. The inventors show herein that the bovine *POLLED* allele was introgressed into horned Holstein fibroblasts. This example demonstrates that various breeds
20 of dairy cattle can be created that do not have horns. And this change can be made without disturbing other genes, or other parts of the genome, of the animals. These processes have been developed by the inventors to achieve efficiencies that are so high that genetic changes can be made without reporters and/or without selection markers. Moreover, the processes can be used in the founder generation to make genetically modified animals that have only the intended
25 change at the intended site. These methods demonstrate meiosis-free intra- and inter-specific introgression of polled and hornless alleles in livestock cells, large mammals, and livestock for research, agricultural and biomedical applications.

Fig. 1 describes experiments for determining if site-specific nucleases could be made that bind to, and cleave, appropriate sites in bovine DNA. One of the problems was to
30 determine if tandem repeats could be bound, bearing in mind that repeated sequences at the desired binding site can confound targeting due to the high likelihood of intermolecular recombination. Moreover, these bindings have to be efficient and mutually cooperate in a live cell in culture. The horned allele, in particular, is a challenge due to the high similarity of polled allele to the horned allele. The chosen location for TALEN binding sites was not

obvious; the TALENs designs that were successful can cleave and bind the horned locus but do not allow TALENs to cleave the polled allele. Discovering these designs was an important achievement in the research of the invention. The success of this approach could not be predicted. As shown in Fig. 1, the horned allele chosen as the target had 212 residues and the
 5 polled allele had a repeat of those 212 residues. The polled allele further had a 10 base pair (bp) deletion in between the repeats. Panel a) depicts the 212 bp sequence, with the 10 bp that are to be deleted at the end, in between the left TALEN (marked by a solid inverted triangle) and the right TALEN (marked by a solid triangle). The TALENs pairs were thus placed on either edge of the 10 bp deletion site. The TALENs pairs cleaved the horned allele in the area
 10 of the 10 bp deletion. A homologous dependent recombination (HDR) template was used to guide insertion of the 212 residue repeat (actually 202 residues since it is a repeat with a 10 bp deletion) between the locations where the TALENs were binding. As depicted in panel a) at Polled, the Left TALEN and Right TALEN are then separated by 202 residues. And recleavage of the polled allele is reduced. Various TALENs were made to determine if binding and
 15 cleavage could be reasonably accomplished. The table in panel b) lists some of the TALENs that were tested. Panel c) shows the test results with their effectiveness measured by the %NHEJ. The TALEN in the third lane, HP1.3, was subsequently used for introgression of polled alleles.

Embodiments for reducing re-binding of a site-specific (also referred to as targeted)
 20 endonuclease include a method of homology-directed repair (HDR) to introgress an exogenous polled allele into chromosomal DNA of a cell, comprising introducing a targeted nuclease system and a HDR template that comprises the exogenous allele into the cell, with the targeted nuclease system comprising a DNA-binding member for specifically binding an endogenous
 25 cognate horned allele sequence in the chromosomal DNA, wherein the targeted nuclease system and the HDR template operate to alter the chromosomal DNA to have identity to the HDR template sequence and to introgress the exogenous allele into the chromosomal DNA in place of an endogenous allele, wherein the HDR template sequence is designed to reduce specific binding of the DNA-binding member to the HDR template sequence.

Fig. 2 shows the research strategy and results for introgression of a polled allele into a
 30 cell with a horned allele. The Horned allele has 1546 bp between PCR primers F1 and R1. In this sequence, there are 365 bp between PCR primers F2 and R2. The horned allele with a 212 bp sequence represented by an arrow is in this area. The *POLLED* allele, bottom, has a tandem repeat of the 212bp (shown as two arrows) with a 10bp deletion (not shown). The length between PCR primers F2 and R2 is 567 bp; the 567 bp equals the 365 bp in the horned allele

plus the 212 bp repeat minus to 10 bp deletion. The length of the HDR template was 1594 bp. Once the template sequence is introgressed into the cell's chromosome, there are 1746 bp between primers F1 and R1; the 1746 equals the 1546 bp of the horned allele plus 212 bp of the repeat minus to 10 bp deletion. Further, a PCR product unique to the polled allele is indicated as P, in the tandem repeat area. TALENs were developed to specifically target the *HORNED* allele (Fig. 1) which could be repaired by homologous recombination using the HDR template. Cells that received the TALENs and HDR template were diluted and plated as single-cells that were cultured and allowed to replicate in clonal colonies. Members of the colonies were tested for the polled allele. Panel b shows representative images of colonies with homozygous or heterozygous introgression of *POLLED*. Three primer sets were used for positive classification of candidate colonies: F1+R1, F2+R2 and F1+P (*POLLED* specific). Identity of the PCR products was confirmed by sequencing F1+R1 amplicons.

Fig. 3 is an example of polled conversion. The polled allele was introgressed into cells in a manner similar to that described for Figs. 1 and 2, except that a different HDR template was used. The template was 591 bp in length: 5'gtctggggtgagatagtttcttgtaggctgtgaaatgaagagtacgtggtaccaactactttctgagctcacgcacagctggacgtctgcgcctttcttgttatactgcagatgaaaacattttatcagatgtttgcctaagtattgattacatttaagatacatattttctttcttgtctgaagtctttgtagtgagagcaggctggaattatgtctggggtgagatagtttctttgctctttagatcaaaactctcttttcattttaagtctatccaaaagtgtgggaggtgtccttgatgttgaattataggcag (SEQ ID NO:14). As indicated by the arrowhead, one of the 12 colonies had a PCR product that demonstrated introgression of the polled allele.

Fig. 4 depicts another scheme for introgression of a polled allele into a cell. A 325 bp HDR template was used. The introgressed allele was Red Angus polled and the recipient was horned Holstein fibroblasts. The template had 29 bp of upstream overlap and 84 bp of downstream overlap. The 212 bp repeat was in between the overlaps. The repeat was used as a replacement for the 10 bp deletion of the native 212 bp sequence. This process was similar to those described in Figs. 1-3 except that a heat denatured (single stranded) oligomer of TALENs was used. As shown in Fig. 4, panels b and c, there were two conditions tested. In panel b), the cells were transfected with 2 µg of TALEN mRNA + 500 ng of ssDNA coated with Gal4:RecA. Each lane/PCR reaction consists of ~3 cell equivalents diluted from a transfected population. PCR using primers btHP-F1 and btHP-R1 from horn cells results in a product of 389 bp. Conversion to polled results in a net insertion of 202 base pairs; thus the PCR product of the same primers results in a 591 bp product (arrow in left margin). The number of reactions with products indicative of polled conversion is shown in the upper right corner. Panel c) PCR assessment of polled conversion in horned Holstein fibroblasts

transfected with 2 ug of TALEN mRNA + 1,500 ng of ssDNA. The number of reactions with products indicative of polled conversion is shown in the upper right corner.

Fig. 5 shows allele introgression with CRISPR/Cas9. This method is compared to a TALENs method. The introgressed allele is Adenomatous polyposis coli (APC). At panel a) the APC14.2 TALENs and the gRNA sequence APC14.2 G1a are shown relative to the wild type *APC* sequence. Below, the HDR oligo is shown which delivers a 4 bp insertion (see boxed section) resulting in a novel HindIII site. Pig fibroblasts transfected with 2 μ M of oligo HDR template, and either 1 μ g TALEN mRNA, 1 μ g each plasmid DNA encoding hCas9 and the guidance RNA (gRNA) expression plasmid; or 1 μ g mRNA encoding hCas9 and 0.5 μ g of gRNA expression plasmid, were then split and cultured at either 30 or 37°C for 3 days before expansion at 37°C until day 10. At panel b) the charts display RFLP and Surveyor assay results. As previously determined, TALEN stimulated HDR was most efficient at 30°C, while CRISPR/Cas9 mediated HDR was most effective at 37°C. For this locus, TALENs were more effective than the CRISPR/Cas9 system for stimulation of HDR despite similar DNA cutting frequency measured by Surveyor assay. In contrast to TALENs, there was little difference in HDR when hCas9 was delivered as mRNA versus plasmid.

In light of the disclosure herein, the creation of polled animals with site-specific endonucleases such as TALENs is taught. One of the barriers to making genetically modified livestock is that the efficiency of making a modification to an animal cell is only a few percent with conventional best practices. Even a low efficiency can be useful for the creation of genetically modified lower animals such as fruit flies or mice because they have short and prolific reproductive cycles that provide for the creating, testing, and screening of hundreds of animals to determine if there are a few that have been successfully modified. These levels of efficiency that are conventionally achieved, however, are not suited to livestock artiodactyls that have much longer gestational times and comparatively few progeny per pregnancy. Another barrier to using genetic tools to modify livestock is that endonuclease-mediated modification of DNA in primary cells is difficult because the cells are unstable. Indeed, the frequency of TALEN-modified cells decreases significantly over time in the absence of enrichment or selection methods. Without being bound to a particular theory, it is theorized that DNA cleavage at non-intended sites can compromise the stability of the cell by inducing apoptosis or disabling non-target genes. The term primary cell means a cell isolated from a living animal, wherein the cell has undergone between 0 and 2 replications since its isolation from the tissue. As a result, techniques customarily used to create and test transformed cells for successful genetic modification can not be used in primary cells due to their propensity to

senesce. As a result, it is unreasonable to expect high rates of success when using conventional approaches that involve modifying a primary cell for somatic cell nuclear transfer or other animal cloning technique. As reported herein, however, TALENs and other site-specific nuclease tools have been used to make genetically modified livestock primary cells. These modifications are suited to making founders of genetically modified animal lines by cloning or direct-embryonic injections.

An embodiment of the invention is a composition and a method for using site-specific endonucleases to genetically modify livestock such as cattle, buffalo, artiodactyls, goat, or sheep so that the animals, and their offspring, do not have horns. Many of the problems making these animals using conventional processes have been discussed above. The genetic modification may be, for example, chosen from the list consisting of an insertion, a deletion, insertion of or change to an exogenous nucleic acid fragment, an inversion, a translocation, interspecies allele migration, intraspecies allele migration, gene conversion to a natural, synthetic, or a novel allele. For instance, an undesired mutation in a chromosome or chromosome pair may be replaced with a normal sequence. In general, a target DNA site is identified and a TALEN-pair is created that will specifically bind to the site. The TALEN is delivered to the cell or embryo, e.g., as a protein, mRNA or by a vector that encodes the TALEN. The TALEN cleaves the DNA to make a double-strand break that is then repaired, often resulting in the creation of an indel, or incorporating sequences or polymorphisms contained in an accompanying exogenous nucleic acid that is either inserted or serves as a template for repair of the break with a modified sequence. The term exogenous nucleic acid means a nucleic acid that is added to the cell or embryo, regardless of whether the nucleic acid is the same or distinct from nucleic acid sequences naturally in the cell. An exogenous sequence refers to a sequence used to change the target cell, regardless of whether the sequence is actually a nucleic acid inserted into chromosomal DNA or if the sequence is used as a template to change the cellular DNA. The term nucleic acid fragment is broad and includes a chromosome, expression cassette, gene, DNA, RNA, mRNA, or portion thereof. The term ssDNA includes ss-oligonucleotides. The cell or embryo may be, for instance, chosen from the group consisting of livestock, an artiodactyl, cattle, swine, sheep, and goat. The term livestock means domesticated animals that are raised as commodities for food or biological material. The term artiodactyl means a hoofed mammal of the order *Artiodactyla*, which includes cattle, deer, camels, hippopotamuses, sheep, and goats that have an even number of toes, usually two or sometimes four, on each foot.

One embodiment is directed to a composition or a method of making a genetically modified livestock that is polled instead of horned comprising introducing a TALEN-pair or other site-specific nuclease system into a cell or an embryo that makes a genetic modification to DNA of the cell or embryo at a site that is specifically bound by the site-specific nuclease (e.g., TALEN-pair), and producing the livestock animal from the cell. Direct injection may be used for the cell or embryo, e.g., into a zygote, blastocyst, or embryo. Alternatively, the site-specific nuclease, HDR template, and/or other factors may be introduced into a cell using any of many known techniques for introduction of proteins, RNA, mRNA, DNA, or vectors. Genetically modified animals may be made from the embryos or cells according to known processes, e.g., implantation of the embryo into a gestational host, or various cloning methods. The phrase “a genetic modification to DNA of the cell at a site that is specifically bound by the TALEN”, or “at a targeted chromosomal site”, or the like, means that the genetic modification is made at the site cut by the nuclease on the TALEN when the TALEN is specifically bound to its target site. The nuclease does not cut exactly where the TALEN-pair binds, but rather at a defined site between the two binding sites.

Another such embodiment involves a composition or a treatment of a cell or embryo to create a polled allele instead of a horned allele. The cell or animal embryo may be used for research, or for cloning the animal. The cell may be of a livestock, artiodactyl, cattle, goat, sheep, a cultured cell, an immortalized cell, a primary cell, a primary somatic cell, a zygote, a germ cell, a primordial germ cell, a blastocyst, or a stem cell. For example, an embodiment is a composition or a method of creating a genetic modification comprising exposing a plurality of primary cells in a culture to TALEN proteins or a nucleic acid encoding a TALEN or TALENs. The TALENs may be introduced as proteins or as nucleic acid fragments, e.g., encoded by mRNA or a DNA sequence in a vector.

The genetic modification of animals to be polled may be made with or without with a reporter. Avoiding a reporter is helpful because it does not later have to be removed, or tolerated if it is not removed. But expression of a reporter at the embryo/cell-level modification stage allows for elimination of cells that do not express the reporter. Alternatively, it allows for moving cells that express the reporter from the culture for use in animals by cloning or other transgenic animal techniques, or into a second culture for further cultivation and/or expansion in number and/or addition of further vectors and/or nucleic acids and/or TALENs and/or other genetic modifications. Selecting cells based on their expression of a reporter that is independent of the gene of interest is a type of co-selection process. The term reporter, as used herein, includes reporters and selection markers. The term selection marker, as used herein,

refers to a genetically expressed biomolecule that confers a trait that permits isolation by either positive or negative survival selection criteria. The reporter may be, e.g., a fluorescent marker, e.g., green fluorescent protein and yellow fluorescent protein. The reporter may be a selection marker, e.g., puromycin, ganciclovir, adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo, G418, APH), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase, thymidine kinase (TK), or xanthin-guanine phosphoribosyltransferase (XGPRT). Other phenotypic markers may be used to select animals; such markers are based on discernible physical traits (e.g., epitopes or color), growth rate, and/or viability. A process for making genetically modified cells, embryos, or animals comprises assaying a cell or embryo exposed to a nuclease-incorporating system, e.g., Cas9 or TALEN, for expression of a reporter and using that cell or embryo in a method or composition for making a genetically modified livestock and/or artiodactyl or other animal (fish, zebrafish, dogs, mice, avian, chicken, rats or a laboratory animal). For instance, a primary cell may be removed from a cell culture and used for cloning. Or, a primary cell may be removed from culture and placed in a second culture to make a clonal line or for further processes. Or, an embryo or zygote expressing the reporter may be used for either implantation into a surrogate dam or can be used for cloning, while other embryos or zygotes that do not express the reporter not used for cloning. In some embodiments, the reporter is a selection marker that is used to select for cells or embryos that express the marker.

Some livestock traits are related to alleles such as polymorphisms (large or small), single nucleotide polymorphisms, deletions, insertions, or other variations. For instance, a myostatin allele (an 11-bp deletion) from Belgian Blue cattle is well known to cause a double-muscling phenotype. The Belgian Blue allele does not interfere with normal development.

Similarly, for the polled allele, the methods taught herein place the allele with precision and without disruption of other genes and without the incorporation of exogenous genes. Since the polled allele relates to the non-development of horns, embryos modified (direct injection or by cloning) to be polled are expected to successfully gestate and result in live births of healthy animals. Cells have been modified from a horned allele to a polled allele and, as of the time of filing, steps have been taken to clone animals from these cells and to generate live birthed animals.

An embodiment of this invention is a method of transfer of a polled allele from a first livestock line or breed to a second livestock line or breed, comprising cutting DNA with a pair of TALENs or a site-specific endonuclease in a cell or embryo of the second livestock line/breed in a presence of a nucleic acid that contains the polled allele of the first livestock

line/breed. The embryo or cell may be used to create an animal of the second line/breed that has the polled allele of the first line/breed. The DNA that contains the allele provides a template for homology-dependent repair. As a template, it has homology to portions of the DNA on each side of the cut and also contains the desired allele.

5 Embodiments of the invention comprise moving a polled allele from one breed to another breed. For instance, alleles may be moved from Angus cattle to other cattle. Horned breeds include: Hereford, Shorthorn, Charolais, Limousin, Simmental, Brahman, Brangus, Wagyu, and Santa Gertrudis, Ayrshire, Brown Swiss, Canadienne, Dutch Belted, Guernsey, Holstein (Holstein-Friesian), Jersey, Kerry, Milking Devon, Milking Shorthorn, Norwegian
10 Red, Busa, Canadienne, Estonian Red, Fleckveih, Frieian, Girolando, Illawarra, Irish Moiled, Lineback, Meuse Rhine Issel, Montbeliared, Normande, Randall, Sahhiwal, Australian Milking Zebu, Simmental, Chianina Marchigiana, Romagnola. Some of the above listed breeds also have polled variants, but the lines in which there genetics are often inferior to the horned version. Examples of polled breeds include: Angus, Red Angus, Red Poll, Galloway,
15 Belted Galloway, American White Park, British White, Amerifax, Jamaica Black, Jamaica Red, Murray Grey, Brangus, Red Brangus, Senopol. As set forth elsewhere herein, the site-specific endonuclease tools, e.g., TALENs, may be delivered as a protein or encoded by a nucleic acid, e.g., an mRNA or a vector. The term breed means a group of domestic animals or plants with a homogeneous appearance, behavior, and other characteristics that distinguish
20 it from other animals or plants of the same species. The animals that belong to a particular breed are known to artisans that practice in these arts.

The term allele means one of two or more forms of a gene or genetic loci. A population or species of organisms typically includes multiple alleles at each locus among various individuals. Allelic variation at a locus is measurable as the number of alleles (polymorphisms)
25 present, or the proportion of heterozygotes in the population. The term natural allele as used herein means an allele found in nature. The term novel allele means a non-natural allele. The term synthetic allele means an allele that is not found in nature. An exogenous allele is one that is introduced into an organism, and the endogenous allele is the one that is naturally in the cell, usually the one that is in the organism in its wild-type unmodified state. Animals that are
30 heterozygous have two alleles. In some cases, it is desirable to introduce an exogenous allele to make an animal homozygous for an allele that is already present in the heterozygous animal. Movement of an allele interspecies means from one species of animal to another and movement intraspecies means movement between animals of the same species.

Two cattle alleles for polled have been identified on chromosome 1 in cattle (Medugorac, 2012). P_C, Celtic origin (212 bp, 1,705,834–1,706,045 bp) is duplicated (and replaces a sequence of 10 bp (1,706,051–1,706,060 bp). Some breeds with this allele include Angus, Galloway, Fleckvieh, Gelbvieh and Murnau-Werdenfelser. A second polled allele of, P_F, is of Friesian origin is characterized by the following, **P5ID** (replace 7 bp (CGCATCA with TTCTCAGAATAG (SEQ ID NO: 26); 1,649,163–1,649,169) and 80,128 bp duplication (1,909,352–1,989,480 bp P80kbID, plus five point mutations at the positions (G1654405A, C1655463T, T1671849G, T1680646C, C1768587A). These changes are generally inherited as a fixed block. All chromosomal coordinates are from the UMD 3.1 cattle genome build.

Animals genetically modified without any reporters; TALENs techniques; Allelic Migrations

Certain embodiments of the invention are directed to processes of modifying cells or embryos without the use of reporters and/or selection markers. In general, it was observed that the frequency of TALEN-modified cells decreases significantly over time in the absence of enrichment or selection methods such as the use of reporter genes. This observation lead to approaches such as the co-transfection, co-selection technique reported herein that involves reporter genes.

It has been discovered, however, that TALENs modification can be performed with an efficiency that is so great that reporters are not needed and their use merely delays the creation of transgenic animal lines. Without being bound to a particular theory, a number of factors independently contributed to the invention of the reporter-free embodiments. One is the realization that TALENs tend to act quickly and at a high efficiency. However, TALENs modifications tended to be unstable over a time frame of several days such that efficiencies can seem to be low depending on the time of sampling. Further, it is conventional wisdom that only stably modified organisms should be used to make transgenic animals so that there is little incentive to understand short-term modifications. There is an incentive to use cell survival genes to select for stable incorporation, as is conventionally done in other systems. Another factor is that TALENs mRNA is unexpectedly effective as compared to vectors that express the TALENs. Direct introduction of mRNA encoding TALENs is, in general, useful, and was used in Examples 8 and 9.

Another factor contributing to discovery of reporter-free embodiments was that there is an unexpected synergy between ssDNA (ss oligonucleotide) templates and TALENs activity. The basis for this synergy is not known. For example, delivery of 0.5-10 micrograms TALEN encoding mRNAs to 500,000-750,000 cells by nucleofection followed by 3 days of culture at

30 degrees Celsius results in consistent levels of modification. But supplementation of these same conditions with 0.2-1.6 nMol of ssODN led to an increase in TALENs activity, as observed by increased NHEJ as assayed by SURVEYOR assay. Typically, a transfection consists of 1-4 micrograms of TALEN mRNA and 0.2-0.4 nMol of ssDNA. Embodiments
5 include introducing to a cell or an embryo, an amount of TALEN mRNA that is more than about 0.05 µg per 500,000 cells, or in a range of from about 0.05 µg to about 100 µg per 500,000 cells; artisans will immediately appreciate that all the ranges and values within the explicitly stated ranges are contemplated. Embodiments include further introducing ssDNA at a concentration of more than about 0.02 nMol or in a range of from about 0.01 to about 10
10 nMol of ssDNA.

The term direct introduction, e.g., direct mRNA introduction, refers to introduction of mRNA material. In contrast, introduction by means of a vector encoding the mRNA is termed indirect introduction. Many processes of direct introduction are known, e.g., electroporation, transfection, lipofection, liposome, nucleofection, biolistic particles, nanoparticles, lipid
15 transfection, electrofusion, and direct injection.

Founder polled animals can be immediately created from modified cells or embryos without the need to create initially modified animals that are subsequently bred to create the basis for a new transgenic line. The term founder or founder animal is used to refer to a first-generation ("F0") transgenic animal that develops directly from the cloned cell or
20 treated/injected embryo that is modified. Methods reported herein provide for creation of founders genetically modified only at the chromosomal target site, and without intermediate steps of breeding and/or inbreeding. Moreover, embodiments include founders that are homozygous for the modification. The founders may be prepared without ever exposing cells and/or embryos to reporter genes (and/or selection marker genes).

25 Embodiments include a method of making a genetically modified polled animal, said method comprising exposing embryos or cells to an mRNA encoding a TALEN, with the TALEN specifically binding to a chromosomal target site in the embryos or cells, cloning the cells in a surrogate mother or implanting the embryos in a surrogate mother, with the surrogate mother gestating an animal that is genetically modified without a reporter gene and only at the
30 chromosomal target site bound by the TALEN. The animal may be free of all reporter genes or may be free of selection markers, e.g., is free of selection markers but has a reporter such as a fluorescent protein. Options include directly introducing the TALENs as mRNA and/or an ss oligonucleotide that provides a template for a genetic modification, e.g., an allele.

A method of making a genetically modified polled animal comprises introducing TALENs and/or vectors into cultured cells, e.g., primary livestock cells. The TALENs are directed to specific chromosomal sites and cause a genetic alteration at the site. An HDR template may also be introduced into the cell, e.g., as a double stranded vector, single stranded DNA, or directly as an ss nucleotide. The cultured cells are subsequently cultured to form colonies of clonal cells. The colonies are tested by PCR and/or sequenced, or otherwise assayed for a genetic modification, preferably without a reporter gene and/or without a selection marker. Cells are taken from colonies that are genetically modified at the intended site and used in cloning. For example, from 10 to 50,000 cells are used to make from 10 to 50,000 embryos that are implanted into surrogates, e.g., in sets of 1-500 embryos per surrogate; artisans will immediately appreciate that all the ranges and values within the explicitly stated ranges are contemplated. Embodiments comprise exposing the cells to the TALEN without a reporter gene, creating colonies of clonal cells, and testing a subset of members of the colonies to identify colonies incorporating the modification at the chromosomal target site.

Processes of making colonies of clonal cells from cultured cells are known. One such method involves dispersing cells from a first culture into a second culture wherein the various cells are not in contact with each other, e.g., by diluting the cells into multiwall plates or into a plate with a relatively large surface area for the number of cells placed therein. The cells are cultured for a period of time that allows the cells to multiply. The multiplying cells are cultured in conditions where they are not likely to move far away from their original location. As a result, a user may observe the cells after the period of time and see various colonies that are all made of a single cell and its progeny. A subset of the cells in the colony may be sampled without destroying the other cells in the colony.

Site-Specific Nuclease Systems

Genome editing tools such as transcription activator-like effector nucleases (TALENs) and zinc finger nucleases (ZFNs) have impacted the fields of biotechnology, gene therapy and functional genomic studies in many organisms. More recently, RNA-guided endonucleases (RGENs) are directed to their target sites by a complementary RNA molecule. The Cas9/CRISPR system is a REGEN. tracrRNA is another such tool. These are examples of targeted nuclease systems: these systems have a DNA-binding member that localizes the nuclease to a target site. The site is then cut by the nuclease. TALENs and ZFNs have the nuclease fused to the DNA-binding member. Cas9/CRISPR are cognates that find each other on the target DNA. The DNA-binding member has a cognate sequence in the chromosomal

DNA. The DNA-binding member is typically designed in light of the intended cognate sequence so as to obtain a nucleolytic action at or near an intended site. Certain embodiments are applicable to all such systems without limitation; including, embodiments that minimize nuclease re-cleavage, embodiments for making SNPs with precision at an intended residue, and
 5 placement of the allele that is being introgressed at the DNA-binding site.

TALENs

The term TALEN, as used herein, is broad and includes a monomeric TALEN that can cleave double stranded DNA without assistance from another TALEN. The term TALEN is
 10 also used to refer to one or both members of a pair of TALENs that are engineered to work together to cleave DNA at the same site. TALENs that work together may be referred to as a left-TALEN and a right-TALEN, which references the handedness of DNA or a TALEN-pair.

The cipher for TALs has been reported (PCT Application WO 2011/072246) wherein each DNA binding repeat is responsible for recognizing one base pair in the target DNA
 15 sequence. The residues may be assembled to target a DNA sequence. In brief, a target site for binding of a TALEN is determined and a fusion molecule comprising a nuclease and a series of RVDs that recognize the target site is created. Upon binding, the nuclease cleaves the DNA so that cellular repair machinery can operate to make a genetic modification at the cut ends. The term TALEN means a protein comprising a Transcription Activator-like (TAL) effector
 20 binding domain and a nuclease domain and includes monomeric TALENs that are functional *per se* as well as others that require dimerization with another monomeric TALEN. The dimerization can result in a homodimeric TALEN when both monomeric TALEN are identical or can result in a heterodimeric TALEN when monomeric TALEN are different. TALENs have been shown to induce gene modification in immortalized human cells by means of the two
 25 major eukaryotic DNA repair pathways, non-homologous end joining (NHEJ) and homology directed repair.

Various working examples for TALENs introduction into cells or embryos, and the formation of animals therefrom are provided herein. Cells for treatment by TALENs include a cultured cell, an immortalized cell, a primary cell, a primary somatic cell, a zygote, a germ
 30 cell, a primordial germ cell, a blastocyst, or a stem cell. Example 10 details experimental results for modifying spermatogonial stem cells. These cells offer another method for genetic modification of animals, e.g., livestock. Genetic modification or gene edits can be executed in vitro in spermatogonial stem cells (male germ-line stem cells, herein abbreviated GSC's) isolated from donor testes. Modified cells are transplanted into germ-cell depleted testes of a

recipient. Implanted spermatogonial stem cells produce sperm that carry the genetic modification(s) that can be used for breeding via artificial insemination (AI) or in vitro fertilization (IVF) to derive founder animals. This method has advantages beyond generation of genetically modified founders. One such advantage is apparent when founders for a particular disease model are unhealthy and not suitable for growth to reproductive age. The same modifications introduced into GSC's could thus be implanted into the testes of a healthy individuals allowing propagation of the line from a healthy animal to generate disease models in newborn piglets.

The possibility and efficiency of generating TALEN-mediated indels in spermatogonial stem cells was first explored by transfection of plasmids encoding TALENs targeted to exon 7 of the porcine Duchene Muscular Dystrophy locus (DMD). Testing of several nucleofection conditions, plasmid quantities and incubation temperature yielded a maximum efficiency of 19% NHEJ despite a germ cell transfection rate of 25%, TALEN activity was highest in replicates cultured at 30°C. GSCs remained viable after over 5 days of culture at 30°C, though overall, germ cell survival was higher at 37°C. Transfection of TALEN encoding mRNA, versus plasmid DNA, resulted in both greater activity and viability of livestock somatic cells and GSCs. Notably, while peak activity of mRNA transfection did not exceed plasmid DNA transfection in this experiment, a significantly lower quantity of mRNA was required to achieve the same level of modification. Example 11 details successful TALEN-stimulated HDR in primordial germ cells (avian).

In some embodiments, a monomeric TALEN can be used. TALEN typically function as dimers across a bipartite recognition site with a spacer, such that two TAL effector domains are each fused to a catalytic domain of the *FokI* restriction enzyme, the DNA-recognition sites for each resulting TALEN are separated by a spacer sequence, and binding of each TALEN monomer to the recognition site allows *FokI* to dimerize and create a double-strand break within the spacer. Monomeric TALENs also can be constructed, however, such that single TAL effectors are fused to a nuclease that does not require dimerization to function. One such nuclease, for example, is a single-chain variant of *FokI* in which the two monomers are expressed as a single polypeptide. Other naturally occurring or engineered monomeric nucleases also can serve this role. The DNA recognition domain used for a monomeric TALEN can be derived from a naturally occurring TAL effector. Alternatively, the DNA recognition domain can be engineered to recognize a specific DNA target. Engineered single-chain TALENs may be easier to construct and deploy, as they require only one engineered DNA recognition domain. A dimeric DNA sequence-specific nuclease can be generated using two

different DNA binding domains (e.g., one TAL effector binding domain and one binding domain from another type of molecule). TALENs may function as dimers across a bipartite recognition site with a spacer. This nuclease architecture also can be used for target-specific nucleases generated from, for example, one TALEN monomer and one zinc finger nuclease monomer. In such cases, the DNA recognition sites for the TALEN and zinc finger nuclease monomers can be separated by a spacer of appropriate length. Binding of the two monomers can allow *FokI* to dimerize and create a double-strand break within the spacer sequence. DNA binding domains other than zinc fingers, such as homeodomains, myb repeats or leucine zippers, also can be fused to *FokI* and serve as a partner with a TALEN monomer to create a functional nuclease.

The term nuclease includes exonucleases and endonucleases. The term endonuclease refers to any wild-type or variant enzyme capable of catalyzing the hydrolysis (cleavage) of bonds between nucleic acids within a DNA or RNA molecule, preferably a DNA molecule. Non-limiting examples of endonucleases include type II restriction endonucleases such as *FokI*, *HhaI*, *HindIII*, *NotI*, *BbvCI*, *EcoRI*, *BglII*, and *AlwI*. Endonucleases comprise also rare-cutting endonucleases when having typically a polynucleotide recognition site of about 12-45 basepairs (bp) in length, more preferably of 14-45 bp. Rare-cutting endonucleases induce DNA double-strand breaks (DSBs) at a defined locus. Rare-cutting endonucleases can for example be a homing endonuclease, a chimeric Zinc-Finger nuclease (ZFN) resulting from the fusion of engineered zinc-finger domains with the catalytic domain of a restriction enzyme such as *FokI* or a chemical endonuclease. In chemical endonucleases, a chemical or peptidic cleaver is conjugated either to a polymer of nucleic acids or to another DNA recognizing a specific target sequence, thereby targeting the cleavage activity to a specific sequence. Chemical endonucleases also encompass synthetic nucleases like conjugates of orthophenanthroline, a DNA cleaving molecule, and triplex-forming oligonucleotides (TFOs), known to bind specific DNA sequences. Such chemical endonucleases are comprised in the term "endonuclease" according to the present invention. Examples of such endonuclease include *I-See I*, *I-Chu L I-Cre I*, *I-Csm I*, *PI-See L PI-Tti L PI-Mtu I*, *I-Ceu I*, *I-See IL I- See III*, *HO*, *PI-Civ I*, *PI-Ctr L PI-Aae I*, *PI-Bsu I*, *PI-Dha I*, *PI-Dra L PI-Mav L PI-Meh I*, *PI-Mfu L PI-Mfl I*, *PI-Mga L PI-Mgo I*, *PI-Min L PI-Mka L PI-Mle I*, *PI-Mma I*, *PI- 30 Msh L PI-Msm I*, *PI-Mth I*, *PI-Mtu I*, *PI-Mxe I*, *PI-Npu I*, *PI-Pfu L PI-Rma I*, *PI-Spb I*, *PI-Ssp L PI-Fae L PI-Mja I*, *PI-Pho L PI-Tag L PI-Thy I*, *PI-Tko I*, *PI-Tsp I*, *I-MsoI*.

Homology directed repair (HDR)

Homology directed repair (HDR) is a mechanism in cells to repair ssDNA and double stranded DNA (dsDNA) lesions. This repair mechanism can be used by the cell when there is an HDR template present that has a sequence with significant homology to the lesion site.

Specific binding, as that term is commonly used in the biological arts, refers to a molecule that binds to a target with a relatively high affinity compared to non-target tissues, and generally involves a plurality of non-covalent interactions, such as electrostatic interactions, van der Waals interactions, hydrogen bonding, and the like. Specific hybridization is a form of specific binding between nucleic acids that have complementary sequences. Proteins can also specifically bind to DNA, for instance, in TALENs or CRISPR/Cas9 systems or by Gal4 motifs. Introgression of an allele refers to a process of copying an exogenous allele over an endogenous allele with a template-guided process. The endogenous allele might actually be excised and replaced by an exogenous nucleic acid allele in some situations but present theory is that the process is a copying mechanism. Since alleles are gene pairs, there is significant homology between them. The allele might be a gene that encodes a protein, or it could have other functions such as encoding a bioactive RNA chain or providing a site for receiving a regulatory protein or RNA.

The HDR template is a nucleic acid that comprises the allele that is being introgressed. The template may be a dsDNA or a single-stranded DNA (ssDNA). ssDNA templates are preferably from about 20 to about 5000 residues although other lengths can be used. Artisans will immediately appreciate that all ranges and values within the explicitly stated range are contemplated; e.g., from 500 to 1500 residues, from 20 to 100 residues, and so forth. The template may further comprise flanking sequences that provide homology to DNA adjacent to the endogenous allele or the DNA that is to be replaced. The template may also comprise a sequence that is bound to a targeted nuclease system, and is thus the cognate binding site for the system's DNA-binding member. The term cognate refers to two biomolecules that typically interact, for example, a receptor and its ligand. In the context of HDR processes, one of the biomolecules may be designed with a sequence to bind with an intended, i.e., cognate, DNA site or protein site.

One embodiment for reducing specific binding to a targeted nuclease system comprises making changes in the HDR template relative to its alignment with the endogenous DNA. One type of change is designed to create mismatches between the cognate members. One change is an insertion or a deletion of one or more residues. Another change is a substitution of one residue for another residue that does not promote binding. The term residue refers to a unit in

a molecular chain, e.g., an amino acid in a protein or a base in a nucleic acid. One place to make the change is at the cognate binding site for the system's DNA-binding member.

Another type of change is designed to interfere with operation of the nucleases by making the change is in the spacer in systems that operate with a spacer, e.g., TALENs pairs, the change may be made in the spacer area. These changes are may include a deletion, e.g., so that the nucleases are hindered from making cuts. These various changes are generally referred to as mismatches herein since they create mismatches when the sequences are aligned; in this context, a deletion, insertion, or substitution is a mismatch. Pairs of nucleases require a spacing that provides a cooperativity; their activity can be disrupted by additions or subtractions to the spacer.

Further embodiments place a mismatch in the exogenous allele. The system's DNA-binding member is designed to bind at a site that at least partially overlaps with the endogenous allele. Once it is introgressed to have identity with the exogenous allele, the DNA-binding member has reduced binding. The DNA-binding member's cognate site thus changes from a preferred endogenous allele to a not-preferred exogenous allele. The cognate site may encompass all of the allele, or just a part of it. It is surprising that the introduction of a mismatch into the exogenous allele is required to stabilize the introgression of the exogenous allele. Apparently the problem of re-cleavage has a very large impact on stability of introgressed alleles. The data that shows this impact was not previously obtained by others because processes with a comparable efficiency are not conventionally available.

Embodiments include creating, with an HDR templating process, mismatches at these various places by insertion, deletion, or substitution of a residue. For instance, from 1-1000 residues may be inserted, deleted, or substituted; artisans will immediately appreciate that all ranges and values within the explicitly stated range are contemplated; e.g., 1-3 residues, at least 10 residues, 4 residues, 4-20 residues, 1-205 residues, 1-220 residues, 1-300 residues, 1-500 residues, 10-1000 residues, and so forth. One or more of these may be combined, e.g., an insertion at one place, a deletion at another, and a substitution at other places.

These various embodiments can be performed in a reporter-free system and to make an SNP or an embodiment relating to an SNP. The cells or animals may be, e.g., livestock, swine, cow, sheep, goat, chicken, rabbit, fish, zebrafish, dog, mouse, cat, rat, and laboratory animal.

Compositions and kits

The present invention also provides compositions and kits containing, for example, nucleic acid molecules encoding site-specific endonucleases, CRISPR, Cas9, ZNFs, TALENs,

polypeptides of the same, compositions containing such nucleic acid molecules or polypeptides, or engineered cell lines. An HDR may also be provided that is effective for introgression of a polled allele. Such items can be used, for example, as research tools, or therapeutically.

5 *Vectors and Nucleic acids*

A variety of nucleic acids may be introduced into the artiodactyl or other cells, for knockout purposes, or to obtain expression of a gene for other purposes. Nucleic acid constructs that can be used to produce transgenic animals include a target nucleic acid sequence. As used herein, the term nucleic acid includes DNA, RNA, and nucleic acid analogs,
 10 and nucleic acids that are double-stranded or single-stranded (i.e., a sense or an antisense single strand). Nucleic acid analogs can be modified at the base moiety, sugar moiety, or phosphate backbone to improve, for example, stability, hybridization, or solubility of the nucleic acid. Modifications at the base moiety include deoxyuridine for deoxythymidine, and 5-methyl-2'-deoxycytidine and 5-bromo-2'-doxycytidine for deoxycytidine. Modifications of the sugar
 15 moiety include modification of the 2' hydroxyl of the ribose sugar to form 2'-O-methyl or 2'-O-allyl sugars. The deoxyribose phosphate backbone can be modified to produce morpholino nucleic acids, in which each base moiety is linked to a six membered, morpholino ring, or peptide nucleic acids, in which the deoxyphosphate backbone is replaced by a pseudopeptide backbone and the four bases are retained. See, Summerton and Weller (1997) *Antisense*
 20 *Nucleic Acid Drug Dev.* 7(3):187; and Hyrup *et al.* (1996) *Bioorgan. Med. Chem.* 4:5. In addition, the deoxyphosphate backbone can be replaced with, for example, a phosphorothioate or phosphorodithioate backbone, a phosphoroamidite, or an alkyl phosphotriester backbone.

The target nucleic acid sequence can be operably linked to a regulatory region such as a promoter. Regulatory regions can be porcine regulatory regions or can be from other species.
 25 As used herein, operably linked refers to positioning of a regulatory region relative to a nucleic acid sequence in such a way as to permit or facilitate transcription of the target nucleic acid.

Any type of promoter can be operably linked to a target nucleic acid sequence. Examples of promoters include, without limitation, tissue-specific promoters, constitutive promoters, and promoters responsive or unresponsive to a particular stimulus. Suitable tissue
 30 specific promoters can result in preferential expression of a nucleic acid transcript in beta cells and include, for example, the human insulin promoter. Other tissue specific promoters can result in preferential expression in, for example, hepatocytes or heart tissue and can include the albumin or alpha-myosin heavy chain promoters, respectively. In other embodiments, a promoter that facilitates the expression of a nucleic acid molecule without significant tissue-

or temporal-specificity can be used (i.e., a constitutive promoter). For example, a beta-actin promoter such as the chicken beta-actin gene promoter, ubiquitin promoter, miniCAGs promoter, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter, or 3-phosphoglycerate kinase (PGK) promoter can be used, as well as viral promoters such as the herpes simplex virus thymidine kinase (HSV-TK) promoter, the SV40 promoter, or a cytomegalovirus (CMV) promoter. In some embodiments, a fusion of the chicken beta actin gene promoter and the CMV enhancer is used as a promoter. See, for example, Xu *et al.* (2001) *Hum. Gene Ther.* 12:563; and Kiwaki *et al.* (1996) *Hum. Gene Ther.* 7:821.

An example of an inducible promoter is the tetracycline (tet)-on promoter system, which can be used to regulate transcription of the nucleic acid. In this system, a mutated Tet repressor (TetR) is fused to the activation domain of herpes simplex virus VP16 trans-activator protein to create a tetracycline-controlled transcriptional activator (tTA), which is regulated by tet or doxycycline (dox). In the absence of antibiotic, transcription is minimal, while in the presence of tet or dox, transcription is induced. Alternative inducible systems include the ecdysone or rapamycin systems. Ecdysone is an insect molting hormone whose production is controlled by a heterodimer of the ecdysone receptor and the product of the *ultraspiracle* gene (USP). Expression is induced by treatment with ecdysone or an analog of ecdysone such as muristerone A. The agent that is administered to the animal to trigger the inducible system is referred to as an induction agent.

Additional regulatory regions that may be useful in nucleic acid constructs, include, but are not limited to, polyadenylation sequences, translation control sequences (e.g., an internal ribosome entry segment, IRES), enhancers, inducible elements, or introns. Such regulatory regions may not be necessary, although they may increase expression by affecting transcription, stability of the mRNA, translational efficiency, or the like. Such regulatory regions can be included in a nucleic acid construct as desired to obtain optimal expression of the nucleic acids in the cell(s). Sufficient expression, however, can sometimes be obtained without such additional elements.

A nucleic acid construct may be used that encodes signal peptides or selectable markers. Signal peptides can be used such that an encoded polypeptide is directed to a particular cellular location (e.g., the cell surface). Non-limiting examples of selectable markers include puromycin, ganciclovir, adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo, G418, APH), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase, thymidine kinase (TK), and xanthin-guanine phosphoribosyltransferase (XGPRT). Such markers are useful for selecting stable transformants in culture. Other selectable markers

include fluorescent polypeptides, such as green fluorescent protein or yellow fluorescent protein.

In some embodiments, a sequence encoding a selectable marker can be flanked by recognition sequences for a recombinase such as, e.g., Cre or Flp. For example, the selectable marker can be flanked by *loxP* recognition sites (34-bp recognition sites recognized by the Cre recombinase) or FRT recognition sites such that the selectable marker can be excised from the construct. See, Orban, et al., *Proc. Natl. Acad. Sci.* (1992) 89:6861, for a review of Cre/lox technology, and Brand and Dymecki, *Dev. Cell* (2004) 6:7. A transposon containing a Cre- or Flp-activatable transgene interrupted by a selectable marker gene also can be used to obtain transgenic animals with conditional expression of a transgene. For example, a promoter driving expression of the marker/transgene can be either ubiquitous or tissue-specific, which would result in the ubiquitous or tissue-specific expression of the marker in F0 animals (e.g., pigs). Tissue specific activation of the transgene can be accomplished, for example, by crossing a pig that ubiquitously expresses a marker-interrupted transgene to a pig expressing Cre or Flp in a tissue-specific manner, or by crossing a pig that expresses a marker-interrupted transgene in a tissue-specific manner to a pig that ubiquitously expresses Cre or Flp recombinase. Controlled expression of the transgene or controlled excision of the marker allows expression of the transgene.

In some embodiments, the target nucleic acid encodes a polypeptide. A nucleic acid sequence encoding a polypeptide can include a tag sequence that encodes a “tag” designed to facilitate subsequent manipulation of the encoded polypeptide (e.g., to facilitate localization or detection). Tag sequences can be inserted in the nucleic acid sequence encoding the polypeptide such that the encoded tag is located at either the carboxyl or amino terminus of the polypeptide. Non-limiting examples of encoded tags include glutathione S-transferase (GST) and FLAG™ tag (Kodak, New Haven, CT).

In other embodiments, the target nucleic acid sequence induces RNA interference against a target nucleic acid such that expression of the target nucleic acid is reduced. For example the target nucleic acid sequence can induce RNA interference against a nucleic acid encoding a cystic fibrosis transmembrane conductance regulatory (CFTR) polypeptide. For example, double-stranded small interfering RNA (siRNA) or short hairpin RNA (shRNA) homologous to a CFTR DNA can be used to reduce expression of that DNA. Constructs for siRNA can be produced as described, for example, in Fire *et al.* (1998) *Nature* 391:806; Romano and Masino (1992) *Mol. Microbiol.* 6:3343; Cogoni *et al.* (1996) *EMBO J.* 15:3153; Cogoni and Masino (1999) *Nature* 399:166; Misquitta and Paterson (1999) *Proc. Natl. Acad.*

Sci. USA 96:1451; and Kennerdell and Carthew (1998) *Cell* 95:1017. Constructs for shRNA can be produced as described by McIntyre and Fanning (2006) *BMC Biotechnology* 6:1. In general, shRNAs are transcribed as a single-stranded RNA molecule containing complementary regions, which can anneal and form short hairpins.

5 Nucleic acid constructs can be methylated using an *SssI* CpG methylase (New England Biolabs, Ipswich, MA). In general, the nucleic acid construct can be incubated with S-adenosylmethionine and *SssI* CpG-methylase in buffer at 37°C. Hypermethylation can be confirmed by incubating the construct with one unit of *HinP1I* endonuclease for 1 hour at 37°C and assaying by agarose gel electrophoresis.

10 Nucleic acid constructs can be introduced into embryonic, fetal, or adult artiodactyl cells of any type, including, for example, germ cells such as an oocyte or an egg, a progenitor cell, an adult or embryonic stem cell, a primordial germ cell, a kidney cell such as a PK-15 cell, an islet cell, a beta cell, a liver cell, or a fibroblast such as a dermal fibroblast, using a variety of techniques. Non-limiting examples of techniques include the use of transposon systems,
15 recombinant viruses that can infect cells, or liposomes or other non-viral methods such as electroporation, microinjection, or calcium phosphate precipitation, that are capable of delivering nucleic acids to cells.

In transposon systems, the transcriptional unit of a nucleic acid construct, i.e., the regulatory region operably linked to a target nucleic acid sequence, is flanked by an inverted
20 repeat of a transposon. Several transposon systems, including, for example, *Sleeping Beauty* (see, U.S. Patent No. 6,613,752 and U.S. Publication No. 2005/0003542); Frog Prince (Miskey *et al.* (2003) *Nucleic Acids Res.* 31:6873); *Tol2* (Kawakami (2007) *Genome Biology* 8(Suppl.1):S7; *Minos* (Pavlopoulos *et al.* (2007) *Genome Biology* 8(Suppl.1):S2); *Hsmar1* (Miskey *et al.* (2007)) *Mol Cell Biol.* 27:4589); and Passport have been developed to introduce
25 nucleic acids into cells, including mice, human, and pig cells. The *Sleeping Beauty* and *Passport* transposon is particularly useful. A transposase can be delivered as a protein, encoded on the same nucleic acid construct as the target nucleic acid, can be introduced on a separate nucleic acid construct, or provided as an mRNA (e.g., an *in vitro*-transcribed and capped mRNA).

30 Nucleic acids can be incorporated into vectors. A vector is a broad term that includes any specific DNA segment that is designed to move from a carrier into a target DNA. A vector may be referred to as an expression vector, or a vector system, which is a set of components needed to bring about DNA insertion into a genome or other targeted DNA sequence such as an episome, plasmid, or even virus/phage DNA segment. Vector systems such as viral vectors

(e.g., retroviruses, adeno-associated virus and integrating phage viruses), and non-viral vectors (e.g., transposons) used for gene delivery in animals have two basic components: 1) a vector comprised of DNA (or RNA that is reverse transcribed into a cDNA) and 2) a transposase, recombinase, or other integrase enzyme that recognizes both the vector and a DNA target sequence and inserts the vector into the target DNA sequence. Vectors most often contain one or more expression cassettes that comprise one or more expression control sequences, wherein an expression control sequence is a DNA sequence that controls and regulates the transcription and/or translation of another DNA sequence or mRNA, respectively.

Many different types of vectors are known. For example, plasmids and viral vectors, e.g., retroviral vectors, are known. Mammalian expression plasmids typically have an origin of replication, a suitable promoter and optional enhancer, and also any necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking non-transcribed sequences. Examples of vectors include: plasmids (which may also be a *carrier* of another type of vector), adenovirus, adeno-associated virus (AAV), lentivirus (e.g., HIV-1, SIV or FIV), retrovirus (e.g., ASV, ALV or MoMLV), and transposons (e.g., *Sleeping Beauty*, *P-elements*, *Tol-2*, *Frog Prince*, *piggyBac*).

As used herein, the term nucleic acid refers to both RNA and DNA, including, for example, cDNA, genomic DNA, synthetic (e.g., chemically synthesized) DNA, as well as naturally occurring and chemically modified nucleic acids, e.g., synthetic bases or alternative backbones. A nucleic acid molecule can be double-stranded or single-stranded (i.e., a sense or an antisense single strand). The term transgenic is used broadly herein and refers to a genetically modified organism or genetically engineered organism whose genetic material has been altered using genetic engineering techniques. A knockout artiodactyl is thus transgenic regardless of whether or not exogenous genes or nucleic acids are expressed in the animal or its progeny.

The nucleic acid sequences set forth herein are intended to represent both DNA and RNA sequences, according to the conventional practice of allowing the abbreviation "T" stand for "T" or for "U", as the case may be, for DNA or RNA. Polynucleotides are nucleic acid molecules of at least three nucleotide subunits. Polynucleotide analogues or polynucleic acids are chemically modified polynucleotides or polynucleic acids. In some embodiments, polynucleotide analogues can be generated by replacing portions of the sugar-phosphate backbone of a polynucleotide with alternative functional groups. Morpholino-modified polynucleotides, referred to herein as "morpholinos," are polynucleotide analogues in which the bases are linked by a morpholino-phosphorodiamidate backbone (see, e.g., U.S. Patent Nos.

5,142,047 and 5,185,444). In addition to morpholinos, other examples of polynucleotide analogues include analogues in which the bases are linked by a polyvinyl backbone, peptide nucleic acids (PNAs) in which the bases are linked by amide bonds formed by pseudopeptide 2-aminoethyl-glycine groups, analogues in which the nucleoside subunits are linked by methylphosphonate groups, analogues in which the phosphate residues linking nucleoside subunits are replaced by phosphoroamidate groups, and phosphorothioated DNAs, analogues containing sugar moieties that have 2' O-methyl group). Polynucleotides of the invention can be produced through the well-known and routinely used technique of solid phase synthesis. Alternatively, other suitable methods for such synthesis can be used (e.g., common molecular cloning and chemical nucleic acid synthesis techniques). Similar techniques also can be used to prepare polynucleotide analogues such as morpholinos or phosphorothioate derivatives. In addition, polynucleotides and polynucleotide analogues can be obtained commercially. For oligonucleotides, examples of pharmaceutically acceptable compositions are salts that include, e.g., (a) salts formed with cations such as sodium, potassium, ammonium, etc.; (b) acid addition salts formed with inorganic acids, for example, hydrochloric acid, hydrobromic acid (c) salts formed with organic acids e.g., for example, acetic acid, oxalic acid, tartaric acid; and (d) salts formed from elemental anions e.g., chlorine, bromine, and iodine.

A sequence alignment is a way of arranging the sequences of DNA, RNA, or protein to identify regions of similarity. Aligned sequences of nucleotide or amino acid residues are typically represented as rows within a matrix, with gaps are inserted between the residues so that identical or similar characters are aligned in successive columns.

Polypeptides

There are a variety of conservative changes that can generally be made to an amino acid sequence without altering activity. These changes are termed conservative substitutions or mutations; that is, an amino acid belonging to a grouping of amino acids having a particular size or characteristic can be substituted for another amino acid. Substitutes for an amino acid sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and tyrosine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Such alterations are not expected to substantially affect apparent molecular weight as determined by polyacrylamide gel

electrophoresis or isoelectric point. Exemplary conservative substitutions include, but are not limited to, Lys for Arg and vice versa to maintain a positive charge; Glu for Asp and vice versa to maintain a negative charge; Ser for Thr so that a free --OH is maintained; and Gln for Asn to maintain a free NH₂. Moreover, point mutations, deletions, and insertions of the polypeptide sequences or corresponding nucleic acid sequences may in some cases be made without a loss of function of the polypeptide or nucleic acid fragment. Substitutions may include, e.g., 1, 2, 3, or more residues. The amino acid residues described herein employ either the single letter amino acid designator or the three-letter abbreviation. Abbreviations used herein are in keeping with the standard polypeptide nomenclature, J. Biol. Chem., (1969), 243, 3552-3559. All amino acid residue sequences are represented herein by formulae with left and right orientation in the conventional direction of amino-terminus to carboxy-terminus.

In some cases a determination of the percent identity of a peptide to a sequence set forth herein may be required. In such cases, the percent identity is measured in terms of the number of residues of the peptide, or a portion of the peptide. A polypeptide of, e.g., 90% identity, may also be a portion of a larger peptide. Embodiments include such polypeptides that have the indicated identity and/or conservative substitution of sequence set forth herein.

The term purified as used herein with reference to a polypeptide refers to a polypeptide that either has no naturally occurring counterpart (e.g., a peptidomimetic), or has been chemically synthesized and is thus substantially uncontaminated by other polypeptides, or has been separated or purified from other most cellular components by which it is naturally accompanied (e.g., other cellular proteins, polynucleotides, or cellular components). An example of a purified polypeptide is one that is at least 70%, by dry weight, free from the proteins and naturally occurring organic molecules with which it naturally associates. A preparation of a purified polypeptide therefore can be, for example, at least 80%, at least 90%, or at least 99%, by dry weight, the polypeptide. Polypeptides also can be engineered to contain a tag sequence (e.g., a polyhistidine tag, a myc tag, or a FLAG[®] tag) that facilitates the polypeptide to be purified or marked (e.g., captured onto an affinity matrix, visualized under a microscope). Thus a purified composition that comprises a polypeptide refers to a purified polypeptide unless otherwise indicated.

Polypeptides may include a chemical modification; a term that, in this context, refers to a change in the naturally-occurring chemical structure of amino acids. Such modifications may be made to a side chain or a terminus, e.g., changing the amino-terminus or carboxyl terminus. In some embodiments, the modifications are useful for creating chemical groups that

may conveniently be used to link the polypeptides to other materials, or to attach a therapeutic agent.

Recombinases

5 Embodiments of the invention include administration of a targeted nuclease system with a recombinase (e.g., a RecA protein, a Rad51) or other DNA-binding protein associated with DNA recombination. A recombinase forms a filament with a nucleic acid fragment and, in effect, searches cellular DNA to find a DNA sequence substantially homologous to the sequence. For instance a recombinase may be combined with a nucleic acid sequence that
10 serves as a template for HDR. The recombinase is then combined with the HDR template to form a filament and placed into the cell. The recombinase and/or HDR template that combines with the recombinase may be placed in the cell or embryo as a protein, an mRNA, or with a vector that encodes the recombinase. The disclosure of US Pub 2011/0059160 (U.S. Serial No. 12/869,232) is hereby incorporated herein by reference for all purposes; in case of conflict, the
15 specification is controlling. The term recombinase refers to a genetic recombination enzyme that enzymatically catalyzes, in a cell, the joining of relatively short pieces of DNA between two relatively longer DNA strands. Recombinases include Cre recombinase, Hin recombinase, RecA, RAD51, Cre, and FLP. Cre recombinase is a Type I topoisomerase from P1 bacteriophage that catalyzes site-specific recombination of DNA between loxP sites. Hin
20 recombinase is a 21kD protein composed of 198 amino acids that is found in the bacteria *Salmonella*. Hin belongs to the serine recombinase family of DNA invertases in which it relies on the active site serine to initiate DNA cleavage and recombination. RAD51 is a human gene. The protein encoded by this gene is a member of the RAD51 protein family which assists in repair of DNA double strand breaks. RAD51 family members are homologous to the bacterial
25 RecA and yeast Rad51. *Cre* recombinase is an enzyme that is used in experiments to delete specific sequences that are flanked by loxP sites. FLP refers to Flippase recombination enzyme (FLP or Flp) derived from the 2 μ plasmid of the baker's yeast *Saccharomyces cerevisiae*.

 Herein, "RecA" or "RecA protein" refers to a family of RecA-like recombination proteins having essentially all or most of the same functions, particularly: (i) the ability to
30 position properly oligonucleotides or polynucleotides on their homologous targets for subsequent extension by DNA polymerases; (ii) the ability topologically to prepare duplex nucleic acid for DNA synthesis; and, (iii) the ability of RecA/oligonucleotide or RecA/polynucleotide complexes efficiently to find and bind to complementary sequences. The best characterized RecA protein is from *E. coli*; in addition to the original allelic form of the

protein a number of mutant RecA-like proteins have been identified, for example, RecA803. Further, many organisms have RecA-like strand-transfer proteins including, for example, yeast, *Drosophila*, mammals including humans, and plants. These proteins include, for example, Rec1, Rec2, Rad51, Rad51B, Rad51C, Rad51D, Rad51E, XRCC2 and DMC1. An
 5 embodiment of the recombination protein is the RecA protein of *E. coli*. Alternatively, the RecA protein can be the mutant RecA-803 protein of *E. coli*, a RecA protein from another bacterial source or a homologous recombination protein from another organism.

Genetically modified animals

10 Various techniques known in the art can be used to introduce nucleic acid constructs into non-human animals to produce founder animals, in which the nucleic acid construct is integrated into the genome. Such techniques include, without limitation, pronuclear microinjection (U.S. Patent No. 4,873,191), retrovirus mediated gene transfer into germ, gene
 15 targeting into embryonic stem cells, electroporation of embryos, sperm-mediated gene transfer (Lavitrano *et al.* (2002) *Proc. Natl. Acad. Sci. USA* 99, 14230-14235; Lavitrano *et al.* (2006) *Reprod. Fert. Develop.* 18, 19-23), and *in vitro* transformation of somatic cells, such as cumulus or mammary cells, or adult, fetal, or embryonic stem cells, followed by nuclear transplantation. Pronuclear microinjection, sperm mediated gene transfer, and somatic cell nuclear transfer are particularly useful techniques, as well as cytoplasmic injection, primordial germ cell
 20 transplantation, and blastocyst chimera production whereby a germ cell is propagated in an embryo.

Typically, in pronuclear microinjection, a nucleic acid construct is introduced into a fertilized egg; 1 or 2 cell fertilized eggs are used as the pronuclei containing the genetic material from the sperm head and the egg are visible within the protoplasm. Pronuclear staged fertilized
 25 eggs can be obtained *in vitro* or *in vivo* (i.e., surgically recovered from the oviduct of donor animals) and *In vitro* fertilized eggs can be produced. For example, in swine, mature oocytes can be fertilized in 500 μ l Minitube PORCPRO IVF MEDIUM SYSTEM (Minitube, Verona, WI) in Minitube 5-well fertilization dishes. In preparation for *in vitro* fertilization (IVF), freshly-collected or frozen boar semen can be washed and resuspended in PORCPRO IVF
 30 Medium to 4×10^5 sperm. Sperm concentrations can be analyzed by computer assisted semen analysis (SPERMVISION, Minitube, Verona, WI). Final *in vitro* insemination can be performed in a 10 μ l volume at a final concentration of approximately 40 motile sperm/oocyte, depending on boar. Incubate all fertilizing oocytes at 38.7°C in 5.0% CO₂ atmosphere for 6 hours. Six hours post-insemination, presumptive zygotes can be washed twice in NCSU-23

and moved to 0.5 mL of the same medium. This system can produce 20-30% blastocysts routinely across most boars with a 10-30% polyspermic insemination rate.

In somatic cell nuclear transfer, a genetically modified cell or blastomere, e.g., an embryonic blastomere, fetal fibroblast, adult ear fibroblast, or granulosa cell, can be introduced into an enucleated oocyte to establish a combined cell. In some conventions, oocytes arrested at meiosis-2 are termed “eggs”. After producing an embryo (e.g., by fusing and activating the oocyte), the embryo is transferred to the oviducts of a recipient female, about 20 to 24 hours after activation. Standard breeding techniques can be used to create animals that are homozygous for the target nucleic acid from initial heterozygous founder animals.

Example 1 TALEN designing and production.

Candidate TALEN target DNA sequences and RVD sequences were identified using the online tool “TAL EFFECTOR NUCLEOTIDE TARGETER”. Plasmids for TALEN DNA transfection or *in vitro* TALEN mRNA transcription were then constructed by following the Golden Gate Assembly protocol using pCGOLDYTALEN (Addgene ID 38143) and RCIscript-GOLDYTALEN (Addgene ID 38143) as final destination vectors (Carlson 2012). The final pC-GoldyTALEN vectors were prepared by using PureLink® HIPURE PLASMID MIDIPREP Kit (Life Technologies) and sequenced before usage. Assembled RCIscript vectors prepared using the QIAPREP SPIN MINIPREP kit (Qiagen) were linearized by SacI to be used as templates for *in vitro* TALEN mRNA transcription using the mMACHINE® T3 Kit (Ambion) as indicated previously (Carlson, 2010). Modified mRNA was synthesized from RCIscript-GOLDYTALEN vectors as previously described (Carlson 2012) substituting a ribonucleotide cocktail consisting of 3'-0-Mem7G(5')ppp(5')G RNA cap analog (New England Biolabs), 5-methylcytidine triphosphate pseudouridine triphosphate (TriLink Biotechnologies, San Diego, CA) and adenosine triphosphate guanosine triphosphate. Final nucleotide reaction concentrations are 6 mM for the cap analog, 1.5 mM for guanosine triphosphate, and 7.5 mM for the other nucleotides. Resulting mRNA was DNase treated prior to purification using the MEGACLEAR REACTION CLEANUP kit (Applied Biosciences).

Example 2 CRISPR/Cas9 design and production.

Gene specific gRNA sequences were cloned into the Church lab gRNA vector (Addgene ID: 41824) according their methods (Mali, 2013). The Cas9 nuclease was provided either by co-transfection of the hCas9 plasmid (Addgene ID: 41815) or mRNA synthesized from RCIscript-hCas9. This RCIscript-hCas9 was constructed by sub-cloning the XbaI-AgeI

fragment from the hCas9 plasmid (encompassing the hCas9 cDNA) into the RCIScript plasmid. Synthesis of mRNA was conducted as above except that linearization was performed using KpnI.

5 Example 3 Donor repair template preparation

A) BB-HDR (1,623bp) plasmid. A 1,695bp fragment encompassing the Belgian Blue allele was PCR amplified (btGDF8 BB 5-1: 5'-CAAAGTTGGTGACGTGACAGAGGTC (SEQ ID NO: 15); btGDF8 BB 3-1: 5'-GTGTGCCATCCCTACTTTGTGGAA (SEQ ID NO: 16)) from Belgian Blue genomic DNA and TOPO cloned into the PCR 2.1 vector (Life Technologies). This plasmid was used as positive control template for analytical primer sets and for derivation of the 1,623bp BB-HDR template by PCR with following primers (BB del HR 1623 5-1: 5'-GATGTATTCCTCAGACTTTTCC (SEQ ID NO: 17); BB del HR 1623 3-1: 5'-GTGGAATCTCATCTTACCAA (SEQ ID NO: 18)) and TOPO cloned as before. Each plasmid was sequence verified prior to use. Transfection grade plasmid was prepared using the Fast-Ion MIDI PLASMID ENDO-FREE kit (IBI Scientific). *rAAV packaging.* BB-HDR was cloned into pAAV-MCS and packaged into using the ADENO-ASSOCIATED VIRUS HELPER-FREE system (Agilent). Briefly, a 10cm dish AAV-293 cells was transfected with 5 µg each: pAAV-Helper, pAAV-RC and the AAV-BB-HDR plasmid. Two days post transfection, the cells were removed from the plate by scraping into 1 ml of growth media. Viral particles were released by 3 freeze-thaw cycles prior to centrifugation at maximum speed in a microcentrifuge for 5 minutes. The supernatant was aspirated and used directly for infection of target cells.

B) Polled 1594 template. A 1,784bp fragment encompassing 383 the POLLED allele was PCR amplified (F1: 5'-GGGCAAGTTGCTCAGCTGTTTTTG (SEQ ID NO: 19); R1- 5'-TCCGCATGGTTTAGCAGGATTCA (SEQ ID NO: 20)) from Angus genomic DNA and TOPO cloned into the PCR 2.1 vector (Life Technologies). This plasmid was used as positive the control template for analytical primer sets and for derivation of the 1,592bp HDR template by PCR with following primers (1594 F: 5'-ATCGAACCTGGGTCTTCTGCATTG (SEQ ID NO: 21); R1: 5'-TCCGCATGGTTTAGCAGGATTCA (SEQ ID NO: 22)) and TOPO cloned as before. Each plasmid was sequence verified prior to use. Transfection grade plasmid was prepared using the Fast-Ion MIDI Plasmid Endo-Free kit (IBI Scientific) and 5 µg or 10 µg was transfected along with 2 µg HP1.3 TALEN mRNA. All oligonucleotide templates were synthesized by Integrated DNA Technologies, 100 nmole synthesis purified by standard desalting, and resuspended to 400 µM in TE.

Example 4 Tissue culture and transfection.

Pig or cattle fibroblasts were maintained at 37 or 30 °C (as indicated) at 5% CO₂ in DMEM supplemented with 10% fetal bovine serum, 100 I.U./ml penicillin and streptomycin, and 2mM L-Glutamine. For transfection, all TALENs and HDR templates were delivered
 5 through transfection using the NEON Transfection system (Life Technologies) unless otherwise stated. Briefly, low passage Ossabaw, Landrace, Wagyu, or Holstein fibroblasts reaching 100% confluence were split 1:2 and harvested the next day at 70-80% confluence. Each transfection was comprised of 500,000-600,000 cells resuspended in buffer "R" mixed with plasmid DNA or mRNA and oligos and electroporated using the 100µl tips by the
 10 following parameters: input Voltage; 1800V; Pulse Width; 20ms; and Pulse Number; 1. Typically, 2-4 µg of TALEN expression plasmid or 1-2 µg of TALEN mRNA and 2-3 µM of oligos specific for the gene of interest were included in each transfection. Deviation from those amounts is indicated in the figure legends. After transfection, cells were divided 60:40 into two separate wells of a 6-well dish for three days' culture at either 30 or 37°C respectively.
 15 After three days, cell populations were expanded and at 37°C until at least day 10 to assess stability of edits.

Example 5 Dilution cloning

Three days post transfection, 50 to 250 cells were seeded onto 10 cm dishes and cultured
 20 until individual colonies reached about 5mm in diameter. At this point, 6 ml of TRYPLE (Life Technologies) 1:5 (vol/vol) diluted in PBS was added and colonies were aspirated, transferred into wells of a 24-well dish well and cultured under the same 420 conditions. Colonies reaching confluence were collected and divided for cryopreservation and genotyping. Sample preparation: Transfected cells populations at day 3 and 10 were collected from a well of a 6-
 25 well dish and 10-30% were resuspended in 50 µl of 1X PCR compatible lysis buffer: 10 mM Tris-Cl pH 8.0, 2 mM EDTA, 0.45% Tryton X-100(vol/vol), 0.45% Tween-20(vol/vol) freshly supplemented with 200 µg/ml Proteinase K. The lysates were processed in a thermal cycler using the following program: 55°C for 60 minutes, 95°C for 15 minutes. Colony samples from dilution cloning were treated as above using 20-30 µl of lysis buffer.

30

Example 6

Detection of *POLLED* introgression was performed by PCR using the F1 primer (see Example 3, above) and the "P" primer (5'-ACGTACTCTTCATTTACAGCCTAC) (SEQ ID NO: 23) using 1X MyTaq Red mix (Bioline) for 38 cycles (95°C, 25 s; 62°C, 25 s; 72°C, 60

s). A second PCR assay was performed using (F2: 5'-GTCTGGGGTGAGATAGTTTTCTTGG (SEQ ID NO: 24); R2- 5'-GGCAGAGATGTTGGTCTTGGGTGT) (SEQ ID NO:25). Candidates passing both tests were analyzed by PCR using the flanking F1 and R1 primers followed by TOPO cloning and sequencing.

Example 7 Amplicon sequencing and analysis.

DNA was isolated from transfected populations and 100-250 ng was added to a 50 µl PLATINUM TAQ DNA POLYMERASE HIGH FIDELITY (Life Technologies) assembled per the manufacturer's recommendations. Each sample was assigned a primer set with a unique barcode to enable multiplex sequencing. A portion of the PCR product was resolved on a 2.5% agarose gel to confirm size prior to PCR cleanup using the MINELUTE PCR PURIFICATION Kit (Qiagen). Samples were quantified and pooled into a single sample for sequencing. The single combined sample was spiked with 25% PhiX (for sequence diversity) and sequenced on an Illumina MISEQ sequencer generating 150 base-pair paired-end reads. Read quality was assessed using FASTQC Read-pairs with overlapping ends were joined using FASTQ-JOIN from the EA-UTILS package. A custom PERL script was used to demultiplex the joined reads and count insert types. Exact matches to the forward and reverse primers were required in the demultiplexing step. Cloned animals were genotyped by RFLP assay and sequencing.

Example 8 Transfection of livestock cells with mRNAs encoding TALENs results in efficient target cleavage.

TALEN cDNA's (TALEN pairs p6511.1 and DMD7.1) were cloned downstream of the T3 promoter in the pT3TS cloning vector transcribed as previously described (Carlson, 2010) and purified using the MINELUTE PCR purification kit (Qiagen) prior to mRNA synthesis using the MMESAGE MACHINE T3 kit (Applied Biosciences) according to the manufacturers protocol. See also Carlson 2013. Modified mRNA was synthesized from the same vectors with the MMESAGE MACHINE T3 kit (Applied Biosciences) substituting a ribonucleotide cocktail consisting of 3'-0-Me-m⁷G(5')ppp(5')G RNA cap analog (New England Biolabs), 5-methylcytidine triphosphate pseudouridine triphosphate (TriLink Biotechnologies, San Diego, CA) and two standard ribonucleotides, adenosine triphosphate and guanosine triphosphate. mRNA synthesis reactions were DNase treated prior to purification using the MEGACLEAR REACTION CLEANUP kit (Applied Biosciences). a) The indicated quantities of p6511.1 TALENs were transfected into pig fibroblasts (500,000-

750,000 cells per replicate) using the NEON nucleofection system (Life Technologies) with the following settings: 1 pulse, 1800 v; 20 ms width and a 100 ul tip. Transfected cells were culture 3 days at either 30 or 37 degrees Celsius prior to indel analysis by the SURVEYOR assay (Transgenomic). Percent NHEJ was calculated as described in Guischin et al., 2010, and plotted on the graph. Four micrograms of plasmid DNA (pDNA) encoding the p6511.1 TALENs was also transfected under the same conditions for comparison of %NHEJ. b) mRNA structure, composition or in vitro synthesis reaction scheme have little effect on TALEN activity. mRNA encoding the DMD7.1 TALENs was synthesized either by individually ("I" left and right TALENs in a separate reaction) or in the same reaction (Dual "D") using standard or modified ribonucleotides. The reactions were then split into two replicates, one of which an additional polyA tail was added using the Poly(A) Tailing Kit (Ambion) according to the manufacturers protocol.

Expression of TALENs from plasmid DNA has been an effective method for induction of TALEN mediated indels in livestock cells; however, integration of the TALEN encoding plasmids into the genomes of cells is possible. In contrast, mRNA cannot integrate into the genomes of host cells. To avoid the integration of TALEN encoding plasmids, an experiment was performed to determine if similar levels of TALEN activity could be achieved by transfection of mRNAs encoding TALENs. mRNA for TALENs encoding the p6511.1 TALEN pair was generated using either standard or modified ribonucleotides. Two quantities of each TALEN mRNA preparation were transfected into pig fibroblasts by nucleofection, cultured 3 days at 30 or 37 degrees Celsius prior to analysis of indels. Percent NHEJ was similar for all mRNA transfections incubated at 30 degrees Celsius while a dosage response could be observed for transfected cells incubated at 37 degrees Celsius. A significant difference in percent NHEJ between modified and standard ribonucleotides could not be detected in this replicate, however, equivalent quantities were not used. Notably, mRNA transfection in all groups incubated at 30 degrees C significantly outperformed the p6511.1 TALENs transfected as plasmid DNA under the same conditions.

Another experiment was performed to examine the influence of modified versus standard nucleotide synthesized mRNA at a second locus, porcine DMD. This experiment also evaluated whether addition of a polyA tail influenced TALEN activity, and whether each TALEN monomer (left and right monomers) could be synthesized in the same transcription reaction (Dual) or if they must be synthesized individually and mixed prior to transfection. One or four micrograms of DMD7.1 TALEN mRNA were transfected into pig fibroblasts and cultured 3 days at 30 or 37 degrees Celsius. As with the p6511.1 TALENs, little difference

was observed in TALEN activity in cells cultured at 30 degrees Celsius suggesting that neither modified nucleotides, in vitro poly adenylation of mRNAs or dual transcription of mRNAs had an influence on activity. A dosage response could again be observed in the 37 degree cultured replicates as 4 µg of mRNA outperformed 1 µg transfections. Also, polyadenylated mRNAs appeared to outperform non adenylated mRNAs in 37 degree replicates.

Notably when plasmid DNA encoding the DMD7.1 TALENs was transfected into pig fibroblasts, a significant reduction (40-60%) in %NHEJ levels measured at day 3 versus cells cultured to day 14 was noticed. No such reduction in %NHEJ was observed for any of the mRNA transfected replicates shown here, data not shown for day 14 modification levels. Thus mRNA transfection appears to be superior to DNA transfection not only for TALEN activity, but also for maintaining a high proportion of modified cells after an extended period in culture. Without being bound to a particular theory, it is believed that this result is due to improved cell viability when transfected with mRNA versus plasmid DNA.

Example 9 Analysis of colonies created by mRNA transfection with no selection.

One to four micrograms of mRNA encoding TALENs were added, as in Example 8, to bovine or swine primary fibroblasts. The cells were grown at 30°C for three days after exposure to TALENs and cells were enumerated and plated at a range of densities 1-20 cells/cm² on 10 cm dishes. Cells were cultured for 10-15 days until individual colonies of 3-4 mm in diameter could be observed. Colonies were aspirated with a p-200 pipettor under gentle aspiration and expelled into a well of 24-well plate with 500 µl of growth medium (Carlson, 2011). Plates with clearly defined colonies (~10-30 / plate) were chosen for colony aspiration to limit the chance of aspirating cells from multiple colonies. Once a colony reached 70-90 percent confluent in the 24-well dish, a portion was harvested for indel analysis and the remainder was cryopreserved. The results of the indel analysis are located in the last five lines of the Table of Genotype distribution in fibroblast clones. These results demonstrate that colonies can be readily isolated from TALEN mRNA transfected fibroblasts without the use of selection markers. Mutation frequency in analyzed clones was accurately predicted by the modification levels of the source population at day 3. Clones with bi-allelic modifications could also be readily identified.

Table of Genotype distribution in fibroblast clones.

TALEN pair	Selection		Day 3 Mod	Predicted % Mod Clones	Predicted % Bi-allelic Mod	Observed Mod Clones (%)	Observed Bi- allelic Mod (%)
LDLRE2.1	Puro	Pig ♂	19	34.5	10.5	30/81 (37)	5/26 (19)
LDLRE2.1	Puro	Pig ♀	21.5	38.3	12	23/76 (30)	8/23 (35) †
LDLRE2.1	Puro	Pig ♂	14.4	26.7	7.7	12/94 (13)	2/12 (≥17) ^A
LDLRE2.1-2x ^B	Puro	Pig	19.7	35.5	10.9	8/24 (33)	2/8 (≥25) ^A
LDLRE4.2	Puro	Pig ♂	20	36	11.1	4/48 (8.3)	¼ (25) ^A
LDLRE4.2	Puro	Pig ♀	19	34.4	10	8/47 (17)	0/8 ^A
DMDE6	Puro	Pig	25	43.8	15.6	17/35 (49)	NA
DMDE7.1	Puro	Pig	27	47	15.6	12/29 (41)	3/10 (30)
DMDE7.1-2x ^B	Puro	Pig	22	39.2	12.4	22/41 (54)	7/22 (≥32) ^A †
GHRHR2.3	G-418	Pig	29	50	17	26/43 (60)	15/26 (≥58) ^C †
ACAN12	Puro	Cow	29	50	17	27/35 (77)	2/6 (NA) ^D
btGDF83.1	Puro	Cow	17	31	9.3	7/24 (29)	0/7
GHRHR2.3	None	Pig ♂	32.5	55	19.4	21/25 (84)	6/21 (≥29) ^A
GHRHR2.3	None	Pig ♀	35	58	21	13/13 (100)	3/13 (≥23) ^A
LDLR2.1	None	Pig ♀	34	57	20	88/166 (53)	5/16 (31%)
btGDF83.1	None	Cow	29	50	17	23/45 (51)	2/23 (≥9) ^E
btGDF83.1	None	Cow	35	58	21	23/41 (56)	7/23 (≥30) ^E

^A Bi-allelic KO were identified by sequencing of PCR products. Only overlapping or homozygous deletions can be identified using this technique.

^B Fibroblasts were transfected and recovered twice within two weeks with the same TALEN pair.

^C 5/15 Bi-allelic colonies were confirmed as double frame-shift alleles.

^D Only colonies with distinguishable gross deletions in the PCR amplicon were analyzed.

^E Bi-allelic KO colonies were identified by high definition melt analysis. Only homozygous modifications can be identified.

†- 95% Confidence interval exceeds expected bi-allelic null hypothesis

Example 10 DNA and mRNA encoded TALENs are active in spermatogonial stem cells.

Porcine germ cells were isolated from 10 wk old boars, and enriched by differential.

- 5 Plasmids encoding eGFP and DMD – specific TALENs were transfected into germ cells using the AMAXA NUCLEOFECTOR system Amaxa solutions “V”- and “L” and “B” using programs X-001 and X-005. See also Carlson 2013. Each transfection reaction was performed with 10⁶ of enriched germ cells, and indicated micrograms of TALEN encoding plasmid DNA. The same methods were used to deliver mRNAs encoding DMD7.1 TALENs. After
- 10 nucleofection, they were cultured for 5 days in 5% CO₂ atmosphere at 37°C or 30°C. Transfection efficiency was evaluated by immunofluorescence analysis for co-localization of expression of GFP and UCH-L1. Cell viability was evaluated by trypan blue exclusion.

Example 11 TALEN stimulated HDR in primordial germ cells.

TALEN stimulated HDR was also tested in chicken primordial germ cells (PGCs) at the chicken Ddx4 locus. Two TALEN pairs were constructed, on to intron 1 (Tal1.1) and exon 7 (Tal7.1) and their function was verified in DF1 chicken cells. See also Example 8 and Carlson 2013. Subsequently, each TALEN pair was co-transfected with the donor targeting vector designed to fuse GFP with Exon 2 of the Ddx4 gene. As expected cleavage with Tal 1.1 stimulated homologous recombination whereas Tal 7., which lies outside of the homologous sequence in the donor targeting vector, did not stimulate HDR.

Example 12 Introgression of the bovine polled allele into horned cells by TALEN stimulated HR.

The polled allele has recently been identified (Medugorac, Seichter et al. 2012), schematic in Figure 1. Four TALEN pairs were designed to cut 3' of the region duplicated in *polled* (Figure 1). Horned Holstein fibroblasts were transfected with mRNA encoding the TALEN pairs and analyzed for activity 3 days post transfection. Surveyor assay revealed activity of each TALEN pair (Figure 1). Peak activity was observed with HP1.3 and thus was chosen for subsequent experiments. Horned Holstein primary fibroblasts were transfected with 2 micrograms of HP1.3 TALEN mRNA along with ssDNA repair templates at the indicated quantities and treatments (Figure 4). Populations of cells three days post transfection were analyzed for conversion to polled by PCR. Coating of the repair template with NLS-RecA-Gal4 (Liao and Essner 2011) had a significant effect on the frequency of polled conversion (Figure 4 panels b and c). Polled conversion was also apparent in individual colonies (Figure 3).

Methods: Approximately 600,000 cells were transfected with the NEON transfection system under the following parameters (1 pulse; 1800 v; 20 ms width). Each transfection consisted to two micrograms of TALEN mRNA along with the indicated repair template. Repair template was coated with Gal4:RecA by the following method. Five hundred nanograms (3 ul total) of repair template PCR product was incubated for 10 min at 95° C and placed on ice for 2 minutes prior to addition of 0.8 ul of buffer [100 mM Tris OAc, pH 7.5; 500mM NaOAc; 10mM DTT; 10mM Mg(OAc)₂], 0.6 ul 16.2mM ATPγS (Sigma) and 1,250 ng of NLS-RecA-Gal4 in a total reaction volume of 8 ul. This reaction was then incubated at 37° C for 30 minutes and placed on ice. The entire volume was used in a single transfection. Cells were cultured and analyzed

using previously described methods (Carlson, Tan et al. 2012). The 591 bp HDR template was used.

Example 13

- 5 Cells made by, or embryos modified by, the methods described herein to introgress polled alleles are cloned and/or placed in surrogate females, gestated, and born as live animals comprising the polled allele.

Further Disclosure

- 10 1. A genetically modified livestock animal comprising a genomic modification from a horned allele to a polled allele. 2. The animal of 1 wherein the animal is a first breed of animal that has the horned allele and the polled allele is found in a second breed of animal. 3. The animal of 1 or 2 wherein the polled allele is selected from the group consisting of a natural allele and a synthetic allele. 4. The animal of 3 wherein the natural allele is
- 15 typical to the breed or is a mutant allele in the breed. 5. The animal of any of 1-4 wherein the first breed is selected from the group consisting of Hereford, Angus, Shorthorn, Charolais, Limousin, Simmental, Brahman, Brangus, Wagyu, and Santa Gertrudis, Ayrshire, Brown Swiss, Canadienne, Dutch Belted, Guernsey, Holstein (Holstein-Friesian), Jersey, Kerry, Milking Devon, Milking Shorthorn, Norwegian Red, Busa,
- 20 Canadienne, Estonian Red, Fleckveih, Frieian, Girolando, Illawarra, Irish Moiled, Lineback, Meuse Rhine Issel, Montbeliared, Normande, Randall, Sahhiwal, Australian Milking Zebu, Simmental, Chianina Marchigiana, Romagnola. 6. The animal of any of 1-5 wherein the second breed is selected from the group consisting of Angus, Red Angus, Red Poll, Galloway, Belted Galloway, American White Park, British White, Amerifax,
- 25 Jamaica Black, Jamaica Red, Murray Grey, Brangus, Red Brangus, Senopol, Boer goats. 7. The animal of any of 1-6 wherein the polled allele is selected from the group consisting of P_C Celtic Origin and P_F Friesian origin. 8. The animal of any of 1-7 being a founder animal or progeny of a founder animal. 9. The animal of any of 1-8 being free of markers and/or free of reporters. 10. The animal of any of 1-9 wherein the genomic modification
- 30 has been made only at the polled allele. 11. The method of 10 wherein the genetically modified organism is chosen from the group consisting of cattle, goats, sheep, and artiodactyls. 12. A use of the animal or a progeny of said animal, of any of 1-11 as livestock. 13. An *in vitro* cell comprising a genomic modification to a horned allele of the cell. 14. The cell of 13 wherein the modification at the horned locus is a modification from the

horned allele to a polled allele. 15. The cell of 13 or 14 wherein the cell is a livestock cell. 16. The cell of any of 13-15 wherein the cell is selected from the group consisting of cattle, goats, sheep, and artiodactyls. 17. The cell of any of 13-15 wherein the cell is a livestock cell selected from the group consisting of Hereford, Angus, Shorthorn, Charolais, Limousin, Simmental, Brahman, Brangus, Wagyu, and Santa Gertrudis, Ayrshire, Brown Swiss, Canadienne, Dutch Belted, Guernsey, Holstein (Holstein-Friesian), Jersey, Kerry, Milking Devon, Milking Shorthorn, Norwegian Red, Busa, Canadienne, Estonian Red, Fleckveih, Frieian, Girolando, Illawarra, Irish Moiled, Lineback, Meuse Rhine Issel, Montbeliared, Normande, Randall, Sahhiwal, Australian Milking Zebu, Simmental, Chianina Marchigiana, and Romagnola. 18. The cell of any of 13-17 wherein the cell is a primary cell, primary somatic cell, or zygote. 19. The cell of any of 13-17 being a livestock stem cell or primordial germ cell. 20. The cell of any of 13-19 comprising, when the cell undergoes the modification, a homologous dependent recombination template encoding a polled allele. 21. The cell of 20 further comprising a site-directed endonuclease to cleave chromosomal DNA at the horned allele of the cell. 22. A use of the cell of any of 12-21 for cloning an animal. 23. An isolated (or synthetic, or separated from nature) nucleic acid encoding a polled allele and comprising a sequence that overlaps with a native horned allele, e.g., as an mRNA and/or an HDR template. 24. A plasmid or other vector to express the isolated nucleic acid of 23. The nucleic acid can be mixed with other components, e.g., as a kit. 25. A method of creating a genetically modified livestock organism comprising altering a native horned allele of a livestock primary cell, a livestock primary somatic cell, a livestock stem cell, a livestock primordial germ cell, a livestock zygote, a livestock blastocyst, or a livestock embryo, with the horned allele being altered to a polled allele. 26. The method of 25 with the livestock being selected from the group consisting of cattle, goats, and sheep. 27. The method of 25 or 26 comprising introducing into the native horned allele of the livestock primary cell, livestock primary somatic cell, livestock stem cell, livestock primordial germ cell, livestock zygote, livestock blastocyst, or livestock embryo: a nucleic acid encoding a site-specific nuclease that specifically cleaves a site in the native horned allele, and a nucleic acid homologous dependent recombination template that comprises the polled allele. 28. The method of any of 25-27 wherein the site-specific nuclease is chosen from the group consisting of a zinc finger nucleases (ZFN), transcriptional activator-like effector nucleases (TALEN) and a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR). 29. The method of any of 25-28 with the primary somatic cell being altered. 30. The method of any of 25-28 with the embryo

being altered. 31. The method of any of 25-28, or 30 further comprising placing the zygote, blastocyst, or embryo into a gestational mother animal. 33. The method of any of 25-29 further comprising cloning the primary cell, primary somatic cell, or zygote to make a whole animal. 34. A livestock animal made with the method of any of 25-32. 34. A use of the methods of any of 25-32 for making a livestock founder animal with a polled phenotype.

*

*

*

*

References

Patent applications, patents, publications, and journal articles set forth anywhere in the specification are hereby incorporated herein by reference for all purposes; in case of conflict, the specification is controlling.

M. CHRISTIAN, et al., *Targeting DNA double-strand breaks with TAL effector nucleases*, 186 Genetics (2010).

J.C. MILLER, et al., *A TALE nuclease architecture for efficient genome editing*, 29 Nature Biotech. (2011).

D. A. MCGREW & K. L. KNIGHT, *Molecular design and functional organization of the RecA protein*, 38 Crit Rev Biochem Mol Biol (2003).

M. M. COX, *Recombinational DNA repair in bacteria and the RecA protein*, 63 Prog Nucleic Acid Res Mol Biol (1999).

B. REISS, et al., *RecA protein stimulates homologous recombination in plants*, 93 Proc Natl Acad Sci U S A (1996).

B. REISS, et al., *RecA stimulates sister chromatid exchange and the fidelity of double-strand break repair, but not gene targeting, in plants transformed by Agrobacterium*, 97 Proc Natl Acad Sci U S A (2000).

O. G. SHCHERBAKOVA, et al., *Overexpression of bacterial RecA protein stimulates homologous recombination in somatic mammalian cells*, 459 Mutat Res (2000).

R. J. YANEZ & A. C. PORTER, *Gene targeting is enhanced in human cells overexpressing hRAD51*, 6 Gene Ther (1999).

Z. CUI, et al., *RecA-mediated, targeted mutagenesis in zebrafish*, 5 Mar Biotechnol (NY) (2003).

N. TAKAHASHI & I. B. DAWID, *Characterization of zebrafish Rad52 and replication protein A for oligonucleotide-mediated mutagenesis*, 33 Nucleic Acids Res (2005).

T. CERMAK, et al., *Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting*, (in press) Nucl. Acids Res. (2011).

D. F. CARLSON, et al., *Strategies for selection marker-free swine transgenesis using the Sleeping Beauty transposon system*, 20 Transgenic Res (2011).

A.M. GEURTS, et al., *Knockout rats via embryo microinjection of zinc-finger nucleases*, 325 Science (2009).

5 I.D. CARBERY, et al., *Targeted genome modification in mice using zinc-finger nucleases*, 186 Genetics (2010).

T. MASHIMO, et al., *Generation of knockout rats with X-linked severe combined immunodeficiency (X-SCID) using zinc-finger nucleases*, 5 PLoS One (2010).

10 L. TESSON, et al., *Knockout rats generated by embryo microinjection of TALENs*, 29 Nat Biotechnol (2011).

C. J. PALGRAVE, et al., *Species-specific variation in RELA underlies differences in NF-kappaB activity: a potential role in African swine fever pathogenesis*, 85 J Virol (2011).

C. MUSSOLINO, et al., *A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity*, Nucleic Acids Res (2011).

15 D. Y. GUSCHIN, et al., *A rapid and general assay for monitoring endogenous gene modification*, 649 Methods Mol Biol (2010).

Y. DOYON, et al., *Transient cold shock enhances zinc-finger nuclease-mediated gene disruption*, 7 Nat Methods (2010).

20 H.J. KIM, et al., *Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly*, 19 Genome Res. (2009).

H. J. LEE, et al., *Targeted chromosomal deletions in human cells using zinc finger nucleases*, 20 Genome Res (2010).

E. E. PEREZ, et al., *Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases*, 26 Nat Biotechnol (2008).

25 D. J. BLAKE, et al., *Function and genetics of dystrophin and dystrophin-related proteins in muscle*, 82 Physiol Rev (2002).

L. GROBET, et al., *A deletion in the bovine myostatin gene causes the double-muscling phenotype in cattle*, 17 Nat Genet (1997).

30 R. KAMBADUR, et al., *Mutations in myostatin (GDF8) in double-muscling Belgian Blue and Piedmontese cattle*, 7 Genome Res (1997).

Carlson, D. F., W. Tan, et al. (2012). "Efficient TALEN-mediated gene knockout in livestock." Proceedings of the National Academy of Sciences.

Liao, H. K. and J. J. Essner (2011). "Use of RecA fusion proteins to induce genomic modifications in zebrafish." Nucleic acids research 39(10): 4166-4179.

Medugorac, I., D. Seichter, et al. (2012). *"Bovine polledness - an autosomal dominant trait with allelic heterogeneity."* PloS one 7(6): e39477.

Carlson et al., (2013) *"Efficient nonmeiotic allele introgression in livestock using custom endonucleases."* Proceedings of the National Academy of Sciences.


What is claimed:

1. A genetically modified livestock animal comprising a genomic modification from a horned allele to a polled allele.
2. The animal of claim 1 wherein the animal is a first breed of animal that has the horned allele and the polled allele is found in a second breed of animal.
3. The animal of claim 1 or 2 wherein the polled allele is selected from the group consisting of a natural allele and a synthetic allele.
4. The animal of claim 3 wherein the natural allele is typical to the breed or is a mutant allele in the breed.
5. The animal of any of claims 1-4 wherein the first breed is selected from the group consisting of Hereford, Angus, Shorthorn, Charolais, Limousin, Simmental, Brahman, Brangus, Wagyu, and Santa Gertrudis, Ayrshire, Brown Swiss, Canadienne, Dutch Belted, Guernsey, Holstein (Holstein-Friesian), Jersey, Kerry, Milking Devon, Milking Shorthorn, Norwegian Red, Busa, Canadienne, Estonian Red, Fleckveih, Frieian, Girolando, Illawarra, Irish Moiled, Lineback, Meuse Rhine Issel, Montbeliaredede, Normande, Randall, Sahhiwal, Australian Milking Zebu, Simmental, Chianina Marchigiana, Romagnola.
6. The animal of any of claims 1-5 wherein the second breed is selected from the group consisting of Angus, Red Angus, Red Poll, Galloway, Belted Galloway, American White Park, British White, Amerifax, Jamaica Black, Jamaica Red, Murray Grey, Brangus, Red Brangus, Senopol , Boer goats.
7. The animal of any of claims 1-6 wherein the polled allele is selected from the group consisting of P_C Celtic Origin and P_F Friesian origin.
8. The animal of any of claims 1-7 being a founder animal or progeny of a founder animal.
9. The animal of any of claims 1-8 being free of markers and/or free of reporters.

10. The animal of any of claims 1-9 wherein the genomic modification has been made only at the polled allele.
11. The method of claim 10 wherein the genetically modified organism is chosen from the group consisting of cattle, goats, sheep, and artiodactyls.
12. A use of the animal or a progeny of said animal, of any of claims 1-11 as livestock.
13. An *in vitro* cell comprising a genomic modification to a horned allele of the cell.
14. The cell of claim 13 wherein the modification at the horned locus is a modification from the horned allele to a polled allele.
15. The cell of claim 13 or 14 wherein the cell is a livestock cell.
16. The cell of any of claims 13-15 wherein the cell is selected from the group consisting of cattle, goats, sheep, and artiodactyls.
17. The cell of any of claims 13-15 wherein the cell is a livestock cell selected from the group consisting of Hereford, Angus, Shorthorn, Charolais, Limousin, Simmental, Brahman, Brangus, Wagyu, and Santa Gertrudis, Ayrshire, Brown Swiss, Canadienne, Dutch Belted, Guernsey, Holstein (Holstein-Friesian), Jersey, Kerry, Milking Devon, Milking Shorthorn, Norwegian Red, Busa, Canadienne, Estonian Red, Fleckveih, Frieian, Girolando, Illawarra, Irish Moiled, Lineback, Meuse Rhine Issel, Montbeliared, Normande, Randall, Sahhiwal, Australian Milking Zebu, Simmental, Chianina Marchigiana, and Romagnola.
18. The cell of any of claims 13-17 wherein the cell is a primary cell, primary somatic cell, or zygote.
19. The cell of any of claims 13-17 being a livestock stem cell or primordial germ cell.
20. The cell of any of claims 13-19 comprising, when the cell undergoes the modification, a homologous dependent recombination template encoding a polled allele.

21. The cell of claim 20 further comprising a site-directed endonuclease to cleave chromosomal DNA at the horned allele of the cell.
22. A use of the cell of any of claims 12-21 for cloning an animal.
23. An isolated nucleic acid encoding a polled allele and comprising a sequence that overlaps with a native horned allele.
24. A plasmid to express the isolated nucleic acid of claim 23.
25. A method of creating a genetically modified livestock organism comprising altering a native horned allele of a livestock primary cell, a livestock primary somatic cell, a livestock stem cell, a livestock primordial germ cell, a livestock zygote, a livestock blastocyst, or a livestock embryo, with the horned allele being altered to a polled allele.
26. The method of claim 25 with the livestock being selected from the group consisting of cattle, goats, and sheep.
27. The method of claim 25 or 26 comprising introducing into the native horned allele of the livestock primary cell, livestock primary somatic cell, livestock stem cell, livestock primordial germ cell, livestock zygote, livestock blastocyst, or livestock embryo:
 - a. a nucleic acid encoding a site-specific nuclease that specifically cleaves a site in the native horned allele, and
 - b. a nucleic acid homologous dependent recombination template that comprises the polled allele.
28. The method of any of claims 25-27 wherein the site-specific nuclease is chosen from the group consisting of a zinc finger nucleases (ZFN), transcriptional activator-like effector nucleases (TALEN) and a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR).
29. The method of any of claims 25-28 with the primary somatic cell being altered.
30. The method of any of claims 25-28 with the embryo being altered.

31. The method of any of claims 25-28, or 30 further comprising placing the zygote, blastocyst, or embryo into a gestational mother animal.
32. The method of any of claims 25-29 further comprising cloning the primary cell, primary somatic cell, or zygote to make a whole animal.
33. A livestock animal made with the method of any of claims 25-32.
34. A use of the methods of any of claims 25-32 for making a livestock founder animal with a polled phenotype.



TALEN ID	Right TALEN (sense strand)	Left TALEN (sense strand)
HP1.1	GAGATAGTTTTCTTGGT	TTTAGATCAAACTCTCTTTTC
HP1.2	AGTTTTCTTGGTAGG	TAGATCAAACTCTCTTTTC
HP1.3	TTTCTTGGTAGGCTG	ATCAAACTCTCTTTTC
HP1.4	TCTTGGTAGGCTGGT	CAAACTCTCTTTTC




FIG. 1

2 / 5





FIG. 2

3 / 5




FIG. 3

4 / 5





FIG. 4

a

APC14.2 TALENs	GGAAGAAAGTATCAGCCAT	ACAGAAATTCTGGGTC-ANTI SENSE STRAND
Wt	CCAGATCGCCAAAGTCATGGAAGAAAGTATCAGCCATTCATCCCTCCCAGAACACAGAAATTCTGGTCAACCCAGGAGTTGCACT	
	APC14.2 G1a	GGGAGGGTCCTTCTGTCTTTAAG-5'
HDR	CCAGATCGCCAAAGTCA C GGAAAGAAAGTATCAGCCATTCATCCCTCCCAG T GAAG CTT ACAGAAATTCTG G TCGACCCAGGAGTTGCACT	




FIG. 5


a.

Horned

Pc HDR

1594 bp

Pc



b.




FIG. 2